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ABSTRACT 
 
Cancer is one of the leading causes of death globally. Current available chemotherapeutics 
are aggressive and not specific to cancer cells, causing damage and death of healthy cells as 
well. As a consequence, the number of side-effects in patients arise. Another important 
therapeutic issue is the development of resistance and/or development of secondary 
malignancies. In some types of cancer, such as hepatocellular carcinoma (HCC) and acute 
monocytic leukaemia (AML), chemotherapy is associated with high mortality rate. This 
points out to the need to search and identify new sources of anti-cancer drugs with high 
selectivity and toxicity only for malignant cells, while conserving healthy cells. 
Marine microalgae are a rich source of different bioactive metabolites (e.g. poly-unsaturated 
fatty acids, carotenoids, polysaccharides, phenols, sterols, vitamins) with anti-inflammatory, 
anti-bacterial, anti-diabetic and anti-hypertensive properties, among others. During the past 
few years, marine microalgae have been featured in cancer research. In this research, we 
studied the cytotoxic effect of six selected microalgae species against adherent (HepG2) and 
suspended (THP-1) human cancer cell lines. 
The ethanolic extract of Phaeodactylum tricornutum was the most bioactive with an IC50 of 
19.4±2.2 µg/mL for HepG2 cells. In addition, this extract was highly selective for HepG2 
cells (SI=4.40) in comparison with a non-tumoural derived cell line (S17). The active extract 
was further subjected to bio-guided fractionation process to obtain four fractions: hexane, 
dichloromethane, ethyl-acetate and water with ethanol. Among these fractions, the 
dichloromethane fraction displayed high cytotoxicity towards both HepG2 and THP-1 cell 
lines with IC50 of 27.5±1.6 and 22.3±1.8 µg/mL, and selectivity of SI>4.54 and SI>5.60, 
respectively. 
In order to tentatively identify compounds responsible for the observable cytotoxic effect, the 
dichloromethane fraction was analysed by gas chromatography – mass spectrometry 
(GC/MS). Thirteen molecules with potential anti-cancer properties were identified, belonging 
to six different classes of metabolites: saturated fatty acids (SFA), polyunsaturated fatty acids 
(PUFAs), sterols, vitamins (dl-α-Tocopherol), phenols and terpenoid alcohols. The most 
abundant compounds detected were hexadecanoic acid, 9-hexadecenoic acid and 
5,8,11,14,17-Eicosapentaenoic acid (EPA). 
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1. INTRODUCTION 
 
1.1. Cancer biology 
Cancer is a global health issue and the second leading cause of death in high-income 
countries and the third leading cause of death in low- and middle-income countries 
worldwide
1
. It is estimated that cancer was responsible for 9.6 million deaths in 2018
2
. Lung, 
prostate, colorectal, stomach and liver cancer are the most common types of cancer in men, 
while breast, colorectal, lung, cervix and thyroid cancer are the most common among 
women
2
. By 2030, it is estimated that the incidence of cancer in the world will grow to over 
21.7 million new cases of disease and lead to 13 million deaths
1
. 
According to current evidence, between 30% and 50% of cancer deaths could be prevented 
simply by avoiding tobacco products, reducing alcohol consumption, maintaining a healthy 
body weight, exercising regularly, and addressing infection-related risk factors
2
. 
The term cancer derives from the Greek word "karkinos", which means crab. Cancer 
encompasses over 100 distinct diseases having in common the abnormal growth of cells that 
invade adjoining parts of the body and/or spread to other organs. Other common terms used 
for cancer are malignant tumours and neoplasms. Cancer can affect almost any organ in the 
human body and has many anatomic and molecular subtypes, that require specific 
management strategies. The oldest written description of cancer known to exist dates back to 
about 1600 BC, but it is believed to be based on a much earlier document, from ca. 3000 BC. 
Hippocrates first used the words carcinos and carcinoma to describe cancer, referring to the 
thick blood vessels that surround and feed the tumours and that resemble the claws of a 
crab
3,4
. 
 
1.1.1. Hallmarks of cancer cells 
Cancer cells differ from normal cells in many ways due to the fact these cells do not respond 
properly to the signals that regulate normal cell behaviour, and consequently cancer cells are 
able to proliferate continuously avoiding cell death
1,3,4
.  
Hanahan and Weinberg (2000) established six hallmarks that are common for all human 
tumours and are responsible for their malignant properties: self-sufficiency in growth signals 
(GS), insensitivity to antigrowth signals, ability to avoid apoptosis, limitless replication 
potential, angiogenesis and capacity to produce metastasis.  
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Self-sufficiency in growth signals. Normal cells need mitogenic growth signals (GS) in order 
to proliferate. Most soluble GSs are produced by one cell type in order to stimulate the 
proliferation of another cell type in a process called heterotypic signalling. Cancer cells, on 
the other hand, have acquired the ability to synthesize their own GSs to which they respond 
by proliferating and creating a positive feedback signalling loop called autocrine stimulation
5
. 
Insensitivity to antigrowth signals. In order to maintain normal tissue homeostasis, many 
antigrowth signals are synthesized and recognized by transmembrane cell surface receptors to 
prevent excessive proliferation. These antigrowth signals can block proliferation either by 
forcing cells from proliferative cycle (G1) back to quiescent state (G0) or by inducing 
permanent loss of proliferative potential of the cell
5,6
. One of the most studied mechanisms of 
negative cell cycle control is the retinoblastoma protein (pRb) pathway. It has been shown 
that pRb is responsible for a major G1 checkpoint, blocking proliferation and progression 
from G1 to S-phase of cell cycle. Cancer cells can disrupt the pRb pathway by releasing 
signalling molecules like TGFβ that prevents phosphorylation, which in turn inactivates pRb. 
In this way tumour cells turn themselves insensitive to antigrowth factors and are able to keep 
proliferating
5,7
.  
Avoiding apoptosis.  There are various strategies through which cancer cells avoid apoptosis. 
One of the most common mechanisms is through a mutation of the p53 tumour suppressor 
gene
5,6
. The p53 is a transcription factor that binds to damaged DNA and promotes tumour 
suppression by two distinct mechanisms. One mechanism includes inducing cell cycle arrest 
in G1 phase and preventing S-phase entry; the other one is promoting apoptosis dependent on 
the Apoptotic Peptidase Activating Factor 1 (Apaf-1)/caspase-9 pathway and involves 
mitochondrial cytochrome c release. However, it remains unclear why certain cells undergo 
apoptosis in response to p53 activation while other cells undergo p53-dependent cell cycle 
arrest. More than half of all types of human cancers have a mutation or missing gene for p53 
resulting in a damaged or missing p53 protein
5,6,8
. As an alternative, cancer cells can 
compromise the activity of p53 by increasing its inhibitors or by silencing the activators of 
p53. One typical example of this is E6 protein produced by human papilloma virus, which 
inactivates p53 and enables cancer cells to evade apoptosis and spread
8
.  
Limitless replication potential. The three acquired capabilities of cancer cells described above 
(self-sufficiency in growth signals, insensitivity to antitumor growth factors and avoiding 
apoptosis) are major responsible factors for tumour malignancies, but still not enough to 
cause macroscopic tumours. Research performed with cultured cell lines over the years 
revealed that after a certain number of cell divisions (60-70) cells stop growing and enter a 
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phase called senescence
9
. After this they slowly start to die. The reason behind this limited 
number of replications is, as it was discovered later, progressive telomeres shortening which 
leads to an inability of DNA polymerases to completely replicate the 3' ends of chromosomal 
DNA. Cancer cells have acquired a mechanism to avoid senescence by maintaining telomere 
length. This is achieved by increased expression of the telomerase enzyme, which adds 
hexanucleotide repeats on the ends of telomeric DNA, keeping the length of telomeres always 
above a certain threshold and assuring constant cell replication.
5,6,9,10
.  
Angiogenesis. The process through which new blood and lymphatic vessels are formed from 
pre-existing vessels is called angiogenesis. This process is essential during foetal 
development, the female reproductive cycle, and for tissue repair. One of the most specific 
and critical regulators of angiogenesis is the vascular endothelial growth factor (VEGF), 
which regulates endothelial proliferation, permeability, and survival; and thrombospondin-1 
(TSP-1), which is an endothelial growth inhibitor. During normal physiological processes 
these two factors are always at equilibrium assuring tissue homeostasis. When tumours are 
present, as they grow, their need for oxygen, nutrients and waste disposal is increasing. 
Because of this, an “angiogenic switch“ is activated in order to sustain the expanding 
neoplastic growth. This is achieved by changing the balance between VEGF and TSP-1, 
mainly through altered gene transcription
6,11
. 
Metastasis. Almost all types of solid tumours during their development enter a process called 
metastasis. Metastasis involves the spread of cancer cells from the primary tumour to the 
surrounding tissues and to distant organs, and it is the primary cause of cancer morbidity and 
mortality. The complete metastatic process consists of the following steps: first, cancer cells 
detach from the primary tumour, and intravasate into the circulatory and lymphatic system 
where they evade immune responses, then extravasation of cells at distant capillary beds 
occurs while invading and proliferating in distant organs. Several hypotheses ,which explain 
the origin of metastasis, exist: epithelial mesenchymal transition, an accumulation of 
mutations in stem cells, a macrophage facilitation process, and a macrophage origin involving 
either transformation or fusion hybridization with neoplastic cells
6,12
. 
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1.1.2. Causes of cancer 
Cancer is a heterogeneous group of diseases with diverse aetiology and pathogenesis. Each 
type of cancer has different mechanism of arising and progressing. Because of that, one 
general cause of cancer cannot be established as a rule. 
There are different hypothesis and explanations for cancer evolution
4
: 
 Genetic changes 
 Epigenetic changes 
 Viruses infection 
 DNA lesions 
Genetic changes. For the past 30 years cancer has been thought to arise from a single cell 
which goes through a series of different genetic alterations causing tumour proliferation, 
invasion, metastasis and drug resistance. This theory is called clonal genetic model. On the 
other hand, the multiple-mutation model, which was proposed later, was based on a belief 
that cancer arises as a result of many different mutations accumulating in different cells over 
time. According to this model, it should take decades for a tumour to arise, and then it should 
also take decades for tumour progression, which is not the case. The genetic instability model 
has been suggested as an alternative model. This model proposes that cancer arises due to an 
accumulation of genetic changes over time, but in specific genes that were found to be altered 
in many cancers – these genes are called oncogenes and tumour-suppressor genes4. Proto-
oncogenes stimulate cell growth, division, and survival. When a proto-oncogene mutates, it 
becomes permanently activated, which enables cells to grow without control and become 
oncogenic. Oncogenes are activated by chromosome rearrangements or gene duplication. 
Tumour suppressor genes normally help to prevent unrestrained cellular growth and promote 
DNA repair and cell cycle checkpoint activation. When they lose their function, cells tend to 
acquire abnormal behaviour
13
. 
Epigenetic changes . Epigenetics is the study of non-sequence-based alterations that are 
inherited through cell division and affect gene expression. Epigenetic alterations do not 
involve changes in the underlying DNA sequence but only phenotype change. Epigenetic 
change is a regular and natural occurrence, but it can also be influenced by several factors 
including age, the environment/lifestyle, and disease state. The most studied epigenetic 
modifications include: DNA hypomethylation, hypermethylation and hypomethylation of 
specific genes, chromatin alterations and loss of imprinting. All these lead to aberrant 
activation of growth-promoting genes and aberrant silencing of tumour-suppressor genes
4,13
.  
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Viral infections. There are some viruses that possess oncogenes and are able to cause cancer. 
The first discovered oncovirus was Rous sarcoma virus (RSV), which causes avian sarcoma 
and was named by its discoverer, Peyton Rous. Thanks to this discovery, many years of 
research led to another important discovery – the first oncogene, v-SRC as well as its cellular 
precursor, c-SRC
3
. Another example of an oncogene virus is the human papillomavirus 
(HPV) that causes a series of transformations on squamous epithelial cells in woman's cervix. 
These transformations, which are called cervical intraepithelial neoplasia (CIN), are 
reversible in the beginning, and the affected part of tissue can be successfully removed. 
However, if CIN is not detected on time, it can progress to irreversible cervical cancer
14
.  
DNA lesions.  One of the most frequent causes amongst all types of cancers are DNA lesions 
which cannot be controlled and arise from human genome instability. It is estimated that 
there are tens of thousands of DNA lesions per cell per day that can corrupt human genetic 
information
3
. 
Factors responsible for DNA lesions occurrence are:  
 chemical reactions (hydrolysis of nucleotide bases and non-enzymatic methylations);  
 occasional mismatches introduced by DNA polymerases during replication and by 
DNA strand breaks generated as a consequence of abortive activities of 
topoisomerases I and II;  
 endogenous agents (reactive oxygen species – ROS, generated through aerobic 
cellular respiration); 
 exogenous agents (UV light, tobacco-derived chemicals and ionizing radiation). 
DNA lesions include adducts, oxidized bases, abasic sites, DNA crosslinks, single-strand 
breaks (SSBs) and, less frequently, double-strand breaks (DSBs)
3
.  
 
1.1.3. Types of cancer 
Cancers are named after the area in which they begin and the type of cells they are made of, 
even if they spread to other parts of the body. 
Carcinoma refers to a cancer that starts in the skin or the tissues that line internal organs 
(liver, lungs, kidneys, intestines, reproductive organs, etc.). 
Sarcoma refers to a cancer of connective tissues such as bones, muscles, cartilage, and blood 
vessels. 
Leukaemia is a cancer of bone marrow, affecting the production of white blood cells 
(monocytes, platelets, granulocytes). 
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Lymphoma is a cancer of the immune system cells (T lymphocytes and B lymphocytes)
15
. 
For the purpose of this Master thesis, the focus was on two different types of cancer: 
hepatocellular carcinoma (HCC), which is fast-growing solid tumour primary in liver, and 
acute monocytic leukaemia (AML), a haematological malignant disorder or “suspended” 
tumour. The major difference between HCC and AML is obviously in their phenotype and 
area where they begin (liver and bone marrow, respectively). Apart from that, it is interesting 
to mention that the prevalence of haematological malignancies is much lower comparing to 
solid tumours, and accounts for only 6,2% of all deaths caused by cancer. However, the 
number of publications in the field of haematological malignancies is much higher than those 
on solid tumours as specimens of malignant cells can be obtained easily from peripheral 
blood of patients
16
.  
 
1.1.4. Hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) is the most common type of primary liver carcinoma. It is 
usually found in people with chronic liver disease and it is a leading cause of cancer-related 
deaths in the world. Despite the fact that huge progress has been made in terms of  
prevention, screening and treatment of HCC, incidence and mortality of this disease continue 
to rise. This carcinoma occurs more often in males than in females (2.4:1), with a higher 
incidence in Eastern and Southern Asia, Middle and Western Africa, Melanesia, and 
Micronesia/Polynesia
17
.  
The main important risk factor for developing HCC is cirrhosis. This is a condition where 
liver is severely damaged and scarring tissue is more abundant than healthy one, 
compromising liver function. Cirrhosis develops over time due to liver damage caused by 
infection with hepatitis B and C viruses and alcohol consumption. Approximately 80% of 
patients infected with hepatitis C develop chronic hepatitis, and ~20% end up developing 
cirrhosis. The development of HCC occurs almost exclusively in livers with already 
established cirrhosis
17
. 
The HCC diagnosis is confirmed without pathologic confirmation. Screening includes 
radiologic tests (ultrasound, computerized tomography, and magnetic resonance imaging), 
and the presence of a serological marker (fetoprotein at 6-month intervals)
17
. 
In spite of all available screening techniques, the majority of patients are not properly 
screened and HCC is many times diagnosed at an already advanced stage when patients are 
symptomatic and liver is severely damaged. A problem at this late stage is that there is no 
effective treatment to improve the survival rate of patients. The treatment option with higher 
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successful rate is surgical resection or liver transplant, which is not always possible. 
Nonsurgical treatments in the form of chemotherapy are usually not successful for HCC 
patients. Moreover, higher mortality rates in HCC are associated with chemotherapy. 
Currently, scientists worldwide are working on finding a new potential therapeutic agent 
which could improve life of HCC patients
17
.  
 
1.1.5. Acute monocytic leukaemia 
Acute myeloblastic leukaemia (AML) is a group of bone marrow neoplasms of myeloid 
precursors of white blood cells. One of the most common types of AML is acute monocytic 
leukaemia (AML-M5) that usually occurs in young children (< 2 years). However, the 
condition is rare and represents approximately 2.5% of all leukaemias during childhood and it 
has an incidence of 0.8 – 1.1 per million per year18.  
The AML-M5 is defined by the presence of more than 20% (WHO classification) or more 
than 30% (French-American-British, FAB classification) of myeloblasts in the bone marrow 
aspirate while normal bone marrow myeloblast count is less than 5%. Malignancy can 
develop as a result of congenital (Down syndrome, Fanconi's anaemia, congenital 
neutropenia) and / or acquired (prenatal exposure to tobacco, alcohol, radiation) factors
18
.  
The symptoms are not specific and include asthenia, pallor, fever, dizziness and respiratory 
failure. More specific symptoms are the appearance of unexplained bruises and/or (excessive) 
bleeding, coagulation disorders (DIC), neurological disorders and gingival hyperplasia. 
Diagnostic methods include blood analysis, bone marrow aspirate for cytochemical, 
immunological and cytogenetical analysis, and cerebrospinal fluid (CSF) investigations
18
.  
Treatment options for AML consist of aggressive multidrug chemotherapy regimens, which 
are associated with high mortality and morbidity. The main drugs used for the treatment of 
AML are: arecytarabine, anthracyclins (daunorubicin, idarubicin and mitoxantrone) and 
etoposide. Therapy protocols include 3-7 courses of drug administration with intervals of 3-4 
weeks. Chemotherapy can have serious consequences as severe bone marrow suppression, 
leading to leukocytopenia, neutropenia and thrombocytopenia. The overall 5-year survival 
rate for AML patients is 30-60% and long-term event free survival rate is only 20-50%. 
Therefore, new therapeutics are needed to increase the probability of cure in this disorder
19
.  
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1.2. Cancer cell lines as in vitro models for cancer research 
Different experimental model systems, both in vivo and in vitro, exist for studying 
pathobiology of cancer. In vivo models include primary tumours, patient-derived xenografts 
and mice. The most used in vitro models are: paraffin-embedded samples, cancer cell lines 
and tumour primary cell cultures. Each of these models is used for different studies due to 
limitations associated with possible genetic manipulation
20
.  
For example, primary tumours (samples obtained by surgery from patients) represent the state 
of the tumour in vivo with its heterogeneity, but only at a specific evolutionary moment of the 
tumour. This sample is difficult to obtain, its amount is limited and genetic manipulation is 
almost impossible
21,22
.  
Patient-derived xenografts in nude mice models are often used for drug testing, providing the 
in vivo microenvironment for human tumour original cells but, on the other hand, they have 
an important limitation – these mice are immune-compromised which contributes to an 
overall inflammation process in cancer.  
Animal models with spontaneous or induced tumours are used in the pathobiology research 
of cancer and for testing new therapeutics in vivo. However, using animal models in research 
means following strict ethical rules and the number of animals is always limited. Apart from 
that, it is difficult to extrapolate obtained results to humans
20
. 
As for in vitro systems, primary cell cultures are good models since they are derived directly 
from the tumours of the patient, which means they maintain some of the heterogeneity of the 
original tumour. However, the tissue environment is lost while culturing and samples are 
scarce and difficult to obtain
20
. 
This brings us to the conclusion that every experimental model for cancer research has certain 
advantages and disadvantages and none of them is completely representative of the 
phenotype of the tumour.  
Nevertheless, cancer cell lines are the most adequate in vitro model for cancer research for 
many reasons. Cell lines are permanently established cell cultures that differ from cell strains 
in that they are immortalize.  E6/E7 gene of human papillomavirus16 (HPV-16), or small and 
large T-antigen of the simian virus 40 (SV-40) are some examples of strategies used for cell 
transformation and immortalization . This means that cell lines will proliferate indefinitely 
given appropriate fresh medium and space, which makes them easy to handle and manipulate. 
Due to the progress in immortalization and cell culture techniques, almost every tissue can be 
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cultured nowadays and there is a large number and variety of cell lines immediately available 
for studying different types of cancer
21
.  
The most important characteristic of cancer cell lines is their high genomic similarity with the 
original tumour. Cancer cell lines maintain the tumour-specific chromosome abnormalities 
and oncogene mutations during the first passages and show the same morphologic and 
molecular characteristics of the primary tumour. In general, cell lines conserve well all 
“hallmarks of cancer” (described in Section 1.1.1), with an exception of angiogenesis due to 
the fact it requires the presence of stromal tissues
20,21
. 
Cancer cell lines also contain cancer stem cells, which makes them an excellent model for 
development and testing of anticancer drugs, which was proven by many scientists over two 
decades ago. Finlay and Bagulay (1984) demonstrated that cancer cell lines display a similar 
response to anticancer drugs when compared to the original tumour. 
However, cancer lines do have some limitations. As the number of cell passages tends to 
increase, cells start to lose their phenotypic properties and become genomically instable. This 
leads to the rise of molecular changes including modifications in cell signalling pathways. 
Because of that, cell culturing for long time periods should be avoided
21,23
.  
To summarize, chosing  the appropriate in vitro model in cancer research is the most 
important step  for the screening of new potential cancer therapies.  The results from the 
research done on cancer cell lines can be extrapolated to in vivo human tumours and this has 
a great importance for drug testing and translational studies.  This characteristic has been 
recognized by many biomedical and pharmaceutical companies
20
.Nevertheless, proper 
molecular characterization (genetic, epigenetic) of cell lines is fundamental before their use 
in order to determine the polygenetic aetiology of the type of cancer studied and the 
molecular mechanisms involved. This enables assessment of different types and subtypes of 
cancer as well as suitability of cell line established for studying that particular cancer type. 
Characterization is especially important for the development of new anticancer drugs as it can 
aid in revealing new targets and it also helps to understand the mechanisms involved in the 
resistance patterns of cells to certain chemotherapeutics
22
. 
As mentioned earlier in this section, there are a large number of cancer cell lines available in 
different culture collections. However, some of them are poorly characterized and may not 
bare the same molecular characteristics as the tumours they represent. In Table 1, the most 
commonly used cancer cell lines are summarized
20
. 
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To conduct this Master Thesis, two cell lines from this list (Table 1) were studied in 
detail – HepG2 and THP-1 cells, representing hepatocellular carcinoma and acute 
monocytic leukaemia, respectively. 
 
Table 1. Summary of most commonly used cancer cell lines with origin in different cell types
20
 
Cancer cell line Species of origin Type of cancer Morphology 
HeLa Homo sapiens Cervix adenocarcinoma Epithelial 
MCF-7 Homo sapiens Brest adenocarcinoma Epithelial 
U87MG Homo sapiens Glioblastoma-astrocytoma Epithelial 
HT-29 Homo sapiens Colon adenocarcinoma Epithelial 
A549 Homo sapiens Lung carcinoma Epithelial 
HepG2  Homo sapiens Hepatocellular carcinoma Epithelial 
K-562 Homo sapiens Chronic myeloid leukaemia Lymphoblast 
THP-1 Homo sapiens Acute monocytic leukaemia Lymphoblast 
PC3 Homo sapiens Prostate adenocarcinoma Epithelial 
A375 Homo sapiens Malignant melanoma Epithelial 
 
1.2.1. HepG2 cell line 
HepG2 is an immortalized cell line consisting of human liver carcinoma cells. It is the most 
widely used human hepatoma cell line and it was derived from a liver hepatocellular 
carcinoma of a 15 year old Caucasian male
23–25
.  
Hepatocellular carcinoma (HCC), the major type of liver cancer, has emerged as the second 
most common cause of cancer-related death. The only approved drug for treating advanced 
HCC, developed so far, is Sorafenib. As previously described in Section 1.1.4, chemotherapy 
used for treating HCC is not successful and is associated with high mortality in patients; 
moreover, liver transplant is the only effective treatment option. Therefore, it is highly 
desirable to develop new drugs for this disease
24
.  
The HepG2 cell line used in this study was obtained from the American Type Culture 
Collection (ATCC® HB-8056™). The morphology of HepG2 cells is epithelial and 
contains 55 chromosome pairs. Cells are adherent and grow as monolayers and in small 
aggregates (Figure 1). HepG2 cells can be grown successfully at large scale, and secrete 
many plasma proteins, such as transferrin, fibrinogen, plasminogen and albumin
26
.  
A detailed summary of HepG2 characteristics provided by ATTC is given in Table 2.  
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Table 2. Main characteristics of HepG2 cell line (ATCC® HB-8065™)26  
 
Characteristics Description 
Karyotype modal number = 55 (range = 50 to 60); has a rearranged chromosome 1 
Receptor expression insulin; insulin-like growth factor II (IGF II) 
Genes expressed 
 
alpha-fetoprotein (alpha fetoprotein); albumin; alpha2 macroglobulin (alpha-2-
macroglobulin); alpha1 antitrypsin (alpha-1-antitrypsin); transferrin; alpha1 
antichymotrypsin; (alpha-1-antichymotrypsin); haptoglobin; ceruloplasmin; 
plasminogen;,complement (C4); C3 activator; fibrinogen; alpha1 acid 
glycoprotein (alpha-1 acid glycoprotein); alpha2 HS glycoprotein (alpha-2-HS-
glycoprotein); beta lipoprotein (beta-lipoprotein); retinol binding protein 
(retinol-binding protein 
 
Cellular products alpha-fetoprotein (alpha fetoprotein); albumin; alpha2 macroglobulin (alpha-2-
macroglobulin); alpha1 antitrypsin (alpha-1-antitrypsin); transferrin; alpha1 
antichymotrypsin; (alpha-1-antichymotrypsin); haptoglobin; ceruloplasmin; 
plasminogen; 
complement (C4); C3 activator; fibrinogen; alpha1 acid glycoprotein (alpha-1 
acid glycoprotein); alpha2 HS glycoprotein (alpha-2-HS-glycoprotein); beta 
lipoprotein (beta-lipoprotein); retinol binding protein (retinol-binding protein) 
 
 
The HepG2 cell line has several advantages comparing to primary cultured human 
hepatocytes: it grows continuously, has almost an unlimited life span and a stable phenotype. 
It is easily available; culture conditions are simpler than primary hepatocytes, and are easily 
standardized among laboratories. These features make the HepG2 cell line appropriate for 
drug screening purposes
24,25
. 
Despite the fact they express many liver-specific functions, the major drawback of this cell 
line is the lack of functional expression of almost all relevant human liver cytochrome P450 
enzymes (CYP) that are involved in phase I of the oxidative metabolism of xenobiotics 
(drugs) system. There are about 50 CYP genes in the human genome encoding for 
catalytically active monooxygenase haemic proteins; however, only a few of them are 
capable to metabolize drugs and xenobiotics, which takes place in the liver. As a 
consequence, HepG2 cell lines show very limited drug metabolism activities and they are 
resistant to most anticancer drugs
23–25
. 
Primary human hepatocytes are still considered the best in vitro model for studying new 
therapeutic agents for hepatocellular carcinoma because they can provide information on how 
12 
 
the potential drug will be metabolized in vivo. Despite this, HepG2 cell lines are usually the 
first option and they are the most commonly used for screening and selection of new drugs as 
they provide the fastest way to identify drug leads with favourable pharmacokinetic and 
metabolic properties; sometimes, they are also the only option
25
.  
 
 
Figure 1.HepG2 (ATCC® HB-8056™)in culture. Cells grow as monolayer forming aggregates: 
A) Low cell density; B) High cell density. Source: www.atcc.org. 
 
1.2.2. THP-1 Cell line 
THP-1 is a human monocytic leukaemia cell line that was firstly cultured from the peripheral 
blood of a 1-year-old male with acute monocytic leukaemia
27,28
. Acute monocytic leukaemia 
(AML) is a malignant disorder that affects hematopoietic cells (bone marrow). Usually 
occurs in young children (< 2 years) and it is associated with high mortality due to aggressive 
chemotherapeutic treatment. New therapies are needed to improve the probability of cure for 
this disease
18,19
.  
The THP-1 cell line is a non-adherent, suspension cell line (Figure 2)
29
. The cells used in this 
study were obtained from the American Type Culture Collection (ATCC® TIB-202™). A 
summary of the main characteristics of THP-1 cell lines is given in Table 3.  
The THP-1 cell line is one of the few leukaemia cell lines available and it is a good model for 
studying acute monocytic leukaemia since it retains monocytic properties (phagocytosis, 
activation of T-lymphocytes, lysozyme production, presence of alpha naphthyl butirate 
esterase) for prolonged period of time in culture conditions (>14 months)
28
.  
 
A B 
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Table 3.Main characteristics of THP-1 cell line (ATCC® TB-202™)29 
 
In addition, upon stimulation with phorbol 12-myristate 13-acetate (PMA), monocyte (THP-
1) cells start to differentiate into macrophage-like cells,becoming adherent. They resemble 
native monocyte-derived macrophages with respect to numerous criteria which makes THP-1 
a valuable model for studying the role of macrophages in human immune response
27,28
. 
Moreover, both monocytes and macrophages play an important part in cancer progression. In 
tumour settings, monocytes are recruited from peripheral blood to the tumour tissue, where 
they differentiate into tumour-associated macrophages (TAM). This subclass of macrophages 
is a heterogeneous cell population regarding their phenotype and pro-tumour function. They 
have abilities to support tumour initiation, local progression and distant metastasis. Therefore, 
targeting monocytes and macrophages in cancer is a promising therapeutic approach
30
. 
 
 
Figure 2. THP-1 (ATCC® TB-202™) in culture. Cells grow in suspension: A) Low cell density; B) 
High cell density.  Source: www.atcc.org. 
 
 
 
 
Characteristics Description 
Karyotype diploid (46, XY); 
Receptor expression 
complement (C3); Fc 
Genes expressed lysozyme,HLA A2, A9, B5, DRw1, DRw2 
Cellular products 
lysozyme 
 
Antigen expression HLA A2, A9, B5, DRw1, DRw2 
A B 
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1.3. Cancer therapy 
There are many types of cancer treatment. The types of treatment that patients receive will 
depend on the type of cancer and its stage of progression
31
. 
According to the National Cancer Institute
31
 available cancer therapies are:  
 Surgery (procedure in which the malignant tissue is removed from the body); 
 Radiation therapy (using high-energy particles or waves, such as X-rays, γ-rays, 
electron beams or protons, in order to destroy or shrink cancer cells); 
 Chemotherapy (special drugs are administered orally or intravenously to stop the 
proliferation of malignant cancer cells); 
 Hormone therapy (slows or stops the growth of cancer cells; used only for prostate 
and breast cancer which need hormones to grow);  
 Immunotherapy (aims to boost human immune system in order to increase production 
of T cytotoxic cells, natural killer (NK) cells, or specific antibodies which target 
cancer cells); 
 Stem cell transplant (bone marrow transplant to induce production of new 
hematopoietic cells, which can increase ability to fight off cancer cells). 
Some patients with cancer will have only one treatment while some will receive a 
combination of treatments, such as surgery with chemotherapy and/or radiation therapy
31
.  
Among all currently used cancer treatments, chemotherapy continues to play an extremely 
important role. However, its effectiveness is limited in some cases by the existence of drug 
resistance, making it necessary to define optimal combinations for therapeutic strategies in 
order to ensure an efficient elimination of the tumour
1
. 
 
1.3.1. Chemotherapeutic agents 
In general, chemotherapeutic agents kill malignant cells causing apoptosis. This was 
demonstrated in vitro with tumour cell lines, as well as in vivo, in patients receiving 
chemotherapy. Apoptosis is a normal cell response to irreparable DNA damage, which leads 
to cell death. There are two major cell-intrinsic pathways for inducing apoptosis. One 
involves inducing the expression of cell surface death receptors (Fas) that bind to ligands 
(FasL), which in turn activate adaptor molecules (FADD) and finally procaspase-8. Another 
pathway involves the release of cytochrome c from mitochondria, binding Apaf-1, and 
activatingprocaspase-9. Once activated, caspase-8 or caspase-9 can in turn activate caspases-
3, 6, and 7
32
. Caspases are a unique family of cysteine-dependent proteases that are 
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responsible for proteolytic cleavages during apoptosis. These cleavages include 
internucleosomal DNA degradation and overall cytoskeleton break up leading to the 
formation of apoptotic bodies. Caspases are present in the cell as inactive zymogens and go 
through a cascade of catalytic activations at the onset of apoptosis
33
. 
Chemotherapeutics are generally classified in five groups: alkylating agents, antimetabolites, 
mitotic inhibitors, topoisomerase inhibitors and tumour antibiotics. Each group has a different 
mechanism of action on cancer cells (Table 4). 
The most widely used antineoplastic drug is etoposide, from the topoisomerase inhibitors 
group
34
. 
 
Table 4.Classification of chemotherapeutic agents with some examples. Source: www.chemocare.com
35
 
Drug class Drug Mechanism 
Alkylating agents Cyclophosphamide, Cisplatin Alkylation of DNA/RNA leading to cross-link between 
DNA strands 
Mitotic inhibitors Vincristine, Docetaxel Destruction of tubulin causing mitotic arrest in metaphase 
Topoisomerase 
inhibitors 
Topotecan, Etoposide Inhibition of topoisomerase I and II causing DNA 
degradation 
Antimetabolites Methotrexate,Hydroxyurea Inhibit ion of DNA replication and prevention of cell growth 
Cancer antibiotics Mitomycin, Actinomycin D Inhibition of RNA synthesis which prevents cell mitosis 
 
1.3.2. Etoposide as a topoisomerase II inhibitor 
DNA topoisomerases are essential enzymes that regulate the topological state of genetic 
material by introducing transient breaks in the DNA molecule. They are involved in 
fundamental biological processes such as DNA replication, transcription, DNA repair and 
chromatin remodelling. Two major topoisomerase forms are present in all cells: type I (Topo 
I) which makes single-strand cuts in DNA, and type II (Topo II) which modulates DNA 
topology by passing an intact helix through a transient double-stranded break created in the 
DNA backbone. As a result, Topo II is able to regulate DNA catenation/decatenation, 
relaxation/supercoiling and knotting/unknotting. The covalent topoisomerase-cleaved DNA 
complex is a short-live intermediate and the breaks created are quickly repaired after passing 
the helix. Etoposide does not directly inhibit the action of Topo II but rather stabilizes this 
covalent cleavage complex introducing more breaks in DNA, which become permanent and 
irreparable. When these permanent DNA breaks are present at sufficient concentration, they 
trigger a series of events that culminate in cell death by apoptosis
32,36,37
.  
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Etoposide is an analogue of 4-demethylepipodophyllin benzylideneglucoside (DEPBG), 
which is a plant toxin obtained from Podophyllum (American Mayapple or Mandrake). 
Podophyllotoxins have been used as medication by various cultures for over 1,000 years and 
were found to be topically effective for skin cancers, although, when ingested, they displayed 
high toxicity
37
.  
Etoposide was first synthesized by Sandoz Pharmaceuticals in 1966 and approved for cancer 
therapy in 1983 by the U.S. Food and Drug Administration. During clinical trials, etoposide 
demonstrated antineoplastic activity in various types of leukaemias, lymphomas and solid 
tumours. Namely, acute monocytic leukaemia (AML), Hodgkin's disease, non-Hodgkin's 
lymphoma, lung cancer (both small cell and non-small cell), gastric cancer, breast cancer and 
ovarian cancer, sarcoma and neuroblastoma. It could be administered both orally and 
intravenously to patients
36,37
. 
However, etoposide, as all chemotherapy drugs, has certain drawbacks. The first issue 
addresses drug specificity. All mammals have two Topo II isoenzymes, Topo II α and β that 
are differently regulated during cell growth. Topo II α is a proliferation marker, greatly 
elevated in tumour cells, whereas the TopoII β is presented in proliferating, as well as post-
mitotic cells. Both isoenzymes are the target of etoposide which leads to off-target toxicity 
destroying not only malignant cells but also healthy cells including white blood cells needed 
for immunity
36,37
. As a consequence, the number of side-effects arise in patients: hair loss, 
low white blood cell count, vomiting, nausea, mouth sores, diarrhoea, fatigue, low blood 
pressure, etc.
38
. Another important therapeutic issue is the development of resistance and/or 
development of secondary malignancies, such as AML
37
. 
These side effects point out to the need to search, find and identify new sources of anticancer 
drugs with high selectivity and toxicity only for malignant cells, while conserving healthy 
immune cells. 
Moreover, in the last decades, with the continuous growth of cancer cases and concerns over 
resistance to certain drugs, development of secondary cancers and the unwanted side effects 
observed, scientists are turning to alternative sources, trying to find potential drug leads in 
natural products (NP)
1
.  
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1.4. The marine environment as promising source of new drug leads 
Natural products (NPs) have been used as a source of therapeutic agents for the treatment of a 
wide spectrum of illnesses for thousands of years. Plants, in particular, have formed the basis 
of traditional medicine with the earliest records from Mesopotamia, around 2600 BCE, where 
usage of approximately 1000 plant-derived substances for curing different disorders was 
documented.
39,40
Even nowadays, many drugs present on the market are plant-derived NPs or 
their derivatives.  
However, since natural product-based drug discovery is sometimes difficult due to their 
complexity, pharmaceutical industry has shifted its focus toward synthetic compound 
libraries for discovery of new drug leads. Unfortunately, obtained results did not meet 
expectations, especially for autoimmune diseases or cancer. This resulted in a declining 
number of new drugs on the market and, at the same time, revitalizing interests for NP. 
Bioactive compounds obtained from NPs are interesting due to their complex chemical 
structures. This complexity is a result of a phenomenon called biodiversity, where the 
interactions between organisms and their environment happen all the time, leading to the 
production of chemical compounds within the organisms, that enhance their survival and 
competitiveness in the environment
39,41,42
. 
Apart from terrestrial organisms, marine organisms have emerged as potential new sources of 
different NPs over the past two decades.  
The systematic investigation of marine environments in order to identify novel biologically 
active compounds started only in the mid-1970s with the development of new technologies in 
scuba diving techniques and engineering of manned submersibles and remotely operated 
vehicles (ROVs) which facilitated exploring and sampling of deep waters
1,40,43
.  
During the period 1977–1987, about 2,500 new metabolites were reported from a variety of 
marine organisms. In 2015, a review performed by Blunt et al. revealed that the number of 
compounds of marine origin reached 30,000 with more than 300 patents waiting for approval. 
Moreover, in their last review from 2018, they reported additional 1277 new compounds 
isolated and described from marine microorganisms and phytoplankton, green, brown and red 
algae, sponges, cnidarians, bryozoans, molluscs, tunicates, echinoderms, mangroves and 
other intertidal plants and microorganisms, only for the year 2016. These numbers suggest 
that the marine environment indeed is a rich source of NPs with uncommon and unique 
chemical features that are not found in terrestrial species. The reason for this is a large 
biodiversity of marine organisms harboured by the oceans. Among 33 animal phyla listed, 32 
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are represented in aquatic environments, with 15 exclusively marine. 17 are found in marine 
and non-marine environments (with 5 of these having more than 95% of their species only in 
marine environments), and only one is exclusively non-marine (Onychophora). It has been 
predicted that approximately 8.9 million of eukaryotic species exist, of which approximately 
2.2 million are marine organisms. This means that around 86% of the species on the earth, 
and 91% in the ocean, have not yet been described
1,41
. 
The coexistence of so many species in marine habitats and constant competition between 
them, as well as demanding environmental conditions (UV light, salinity, temperature, high 
pressure), resulted in the development of different mechanisms by marine organisms to 
defend themselves against predation or overgrowth of competing species. These mechanisms 
are actually chemical adaptions, defined as secondary metabolites that involve different 
classes of chemical compounds. They are generally specific for a particular taxonomic 
family, genus, species or even organism, and constitute a very small fraction of the total 
biomass of the organism. Predominantly, production of these NPs with excellent 
pharmacological potential occurs in sessile or slow-moving organisms (e.g. algae, sponges, 
cnidarians, tunicates and bryozoans) that, without effective escape mechanisms or structural 
protection, ensure their protection through chemical defence. Moreover, high 
pharmacological activity of NPs obtained from marine organisms comes from the fact that 
these compounds are released to the water and are rapidly diluted, therefore, they have to be 
highly potent to retain their efficacy
1,40,41,43
.  
To date, different types of secondary metabolites were isolated from marine organisms: 
terpenoids, alkaloids, polyketides, peptides, shikimic acid derivatives, sugars, steroids, and a 
large mixture of biogenesis metabolites. These compounds were found to exhibit many 
biological activities (antimicrobial, anti-tumoural, anti-diabetic, anticoagulant, antioxidant, 
anti-inflammatory, antiviral, antimalarial, anti-tubercular, anti-aging antifouling, and 
antiprotozoal) with huge industrial and therapeutic potentials
1,41,43
. 
The current pipeline for new compounds, from the initial demonstration that a molecule may 
have therapeutic potential to the production and approval, a drug needs to pass pre-clinical 
testing, complex clinical trials in humans, and post-trial approval by the regulatory organisms  
- Food and Drug Administration (FDA) (in US) and European Medicines Agency (EMA) 
(EU). This process can take 10 to 15 years with less than 12% of the potential drugs receiving 
final approval
44
.  
To date, seven approved marine-derived pharmaceuticals are in clinical use, four of which are 
anticancer drugs. The first marine derived anticancer agent developed for clinical use, 
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cytarabine or Ara-C, is a synthetic analogue of a C-nucleoside from the Caribbean sponge, 
Cryptothethya crypta, approved in 1969 and still in use for the treatment of acute myelocytic 
leukaemia and non-Hodgkin’s lymphoma. Another example is Aplidine (dehydrodidemnin B) 
developed by PharmaMar
©
. This depsipeptide hydrodidemnin was isolated from the 
Mediterranean tunicate Aplidiumalbicans, and used in the treatment of multiple myeloma 
(phase III of clinical trials), and for solid and haematological malignant neoplasias, like T-
cell lymphoma (phase II of clinical trials)
45
. 
 
1.4.1. Marine microalgae as a novel source of anti-tumoural drugs 
Among marine organisms, algae and microalgae are one of the most important resources of 
the ocean, economically and ecologically. Microalgae are microscopic, photosynthetic 
organisms found in both marine and freshwater environments and represent the major 
component of phytoplankton. They are primary producers, responsible for up to 50% of 
global carbon fixation. Their photosynthetic mechanism is similar to that of land-based 
plants, converting solar energy into biomass, mainly because of their simple cellular structure 
and being submerged in an aqueous environment with access to water, CO2, and other 
nutrients
46,47
.  
Microalgae are a polyphyletic and highly diverse group of prokaryotic and eukaryotic 
organisms
48
. The classification into divisions is based on various properties: pigmentation, 
chemical nature of photosynthetic storage products, the organization of photosynthetic 
membranes, and other morphological features. The most abundant microalgal classes are: 
Cyanophyceae (blue-green and red algae), Chlorophyceae (green algae), Bacillariophyceae 
(diatoms), Chrysophyceae (including golden algae) and Phaeophyceae (brown algae)
46,49
. 
Microalgae are considered as one of the most promising sources for new products and 
applications due to their chemical composition. These organisms are rich in important 
biomolecules such as polyunsaturated fatty acids (PUFAs), pigments (chlorophylls and 
carotenoids), polyphenolic compounds, phycobilins, vitamins, sterols and polysaccharides. It 
has been found that these biomolecules have not only nutritional value but also display 
bioactivities and have a potential use as therapeutic agents in the biomedical area. Many of 
these algae-derived compounds have been associated with numerous health promoting effects 
including anti-obesity, anti-diabetic, antihypertensive, anti-hyperlipidaemia, antioxidant, 
anticoagulant, anti-inflammatory, immune-modulatory, anti-estrogenic, thyroid-stimulating, 
neuroprotective, anti-osteoarthritic, anti-osteoporosis, antiviral, antimicrobial and anti-
tumoural (Table 5)
44,50,51
. 
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Table 5.Bioactive compounds obtained from microalgae ant their effect on human health
49–51
 
 
Bioactive compound isolated Health-promoting effect Microalgae 
Carotenoids   
β-carotene antioxidant activity 
Dunaliellasalina; Haematococcus 
pluvialis; Tetraselmisspp. 
astaxanthin 
antioxidant, immunomodulation, 
and cancer prevention 
H.pluvialis; Chlorella vulgaris 
fucoxanthin 
antioxidant, immunomodulation, 
and cancer prevention 
Isochrysisgalbana; Phaeodactylum 
tricornutum 
lutein antioxidant activity Chlorella pyrenoidosa; Tetraselmis spp. 
violaxanthin antioxidant activity 
Chlorella ellipsoidea; 
Nannochloropsisoculata; Tetraselmis 
spp. 
PUFAs   
eicosapentaenoic acid (EPA) 
reduce risk of certain heart 
diseases, anticoagulation,anti-
inflammatory, neuroprotective 
P.tricornutum;Porphyridiumcruentum; 
I. galbana 
oleic acid antioxidant activity 
C. vulgaris; H.pluvialis; 
Spirulinaplatensis 
linoleic acid antimicrobial activity D.salina; S.platensis 
palmitic acid antimicrobial activity D.salina 
palmitoleic acid Antihypertensive S.platensis 
Docosahexaenoic acid (DHA) 
reduce risk of certain heart 
diseases, anticoagulation,anti-
inflammatory, neuroprotective 
S.platensis 
Proteins   
Phycobiliproteins 
immunomodulation activity, 
anticancer activity, 
hepatoprotective, anti-
inflammatory, and 
antioxidant properties 
S.platensis; Porphyridium spp. 
Polysaccharides   
sulfated polysaccharide 
antiviral, antitumor, 
antihyperlipidemia, 
and anticoagulant 
C. pyrenoidosa; Porphyridium spp. 
Insoluble fiber 
 
reduce total and LDL cholesterol C. vulgaris 
Vitamins   
tocopherols (vitamin E) antioxidant activity 
S.platensis; Porphyridium spp., 
Tetraselmisspp 
Phenolic compounds   
benzoic acid derivatives, 
hydroxybenzaldehydes, and 
cinnamic acid derivatives 
antioxidant activity S.platensis 
 
Along the last five decades it is estimated that more than 3,000 NPs have been discovered 
from algae and among all of the mentioned biological activities, anti-tumoural activity seems 
to be one of the most promising
44
. Many studies demonstrated the in vitro cytotoxicity of 
different extracts (water, ethanol, ethyl acetate, hexane, acetone) obtained from microalgal 
biomass on tumoural cell lines (Table 6). 
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   Table 6. In vitro cytotoxicity of microalgae on cancer cell lines 
Microalgae Extract tested Cell line IC50 (μM or 
μg/mL) 
Compound 
responsible (if 
applicable) 
Observed effects on cells (if 
applicable 
Spirulina 
platensis
52
 
water Colon carcinoma(HCT116), 
hepatocellular carcinoma (HepG2) 
18.8 μg/mL for 
HCT116; 22.3 
μg/mL for HepG2 
  
Porphyridium 
purpureum
53
 
isolated and purified 
carotenoid 
Human melanoma (A2058) 40 µM zeaxanthin Chromatin condensation, nuclear 
blebbing, DNA nucleosomal 
fragmentation, activation of caspase-
3 (apoptosis) 
Nitzschia sp
54
 isolated and purified 
carotenoid 
Human glioma (U251)  fucoxanthin Induction of apoptosis with PARP 
cleavage and caspase activation 
Isocrysis 
galbana
55
 
acetone HepG2 81.3 μg/mL  Showed high selectivity (3.1) 
comparing to non-tumoural, murine 
stromal S17 cell line 
Chaetoceros 
calcitrans
56
 
hexane, 
dichloromethane, ethyl 
acetate and methanol 
Breast adenocarcinoma (MDA-MB-231) 
, mouse breast carcinoma (4T1), HepG2, 
cervix epithelial carcinoma (HeLa), 
human prostate carcinoma (PC-3), 
human lung adenocarcinoma (A549), 
human colon adenocarcinoma (HT-29) 
60 µg/mL, ethyl 
acetate extract on 
the MDA-MB-231 
cancer cell line 
 Extract did not show cytotoxicity on 
non-tumorigenic cells (mouse 
embryo fibroblast (3T3)) 
Porphyridium 
cruentum
64
 
sulfoglyco-lipidic 
fraction (SF) 
Colon adenocarcinoma (DLD-1), human 
breast adenocarcinoma (MCF-7), human 
prostate adenocarcinoma (PC-3), and 
human malignant melanoma (M4) 
20-46 µg/mL 
(range applies to all 
tested cell cultures) 
sulfolipids Inhibition of DNA α polymerase 
Skeletonema 
costatum
67
 
organic extract human non-small-cell 
bronchoplumanory carcinoma line 
(NSCLC-N6) 
 
  G1 cell cycle arrest 
Phaeodactylum 
tricornutum 
       ethanol HepG2 250 µg/mL Sulphated 
polysaccharide 
 
Nannochloropsis 
oculata 
      methanol human chronic myeloid 
leukemia cell line (K562) 
50 µg/mL  Induction of apoptosis with PARP 
cleavage and caspase activation 
 22 
 
Despite the number of compounds isolated from microalgae and biological activities 
attributed to these, they still have not entered clinical trials or been marketed.
,51,57
. 
There are several reasons for this, including the time and cost it takes to reach the market, 
difficulties in harvesting the organism, low titres of natural product in producing organisms, 
difficulties in isolation and purification procedures, problems in obtaining a sustainable 
supply of the compound, high toxicity of the active compound, ecological impact on natural 
populations, and insufficient investment by pharmaceutical companies
45
. In spite of the high 
number of microalgae species identified, only a few of them have been successfully 
commercialized for biotechnological applications. 
Examples are Chlorella spp. (production of lutein)
57
, Spirulina platensis (production of 
phycobiliproteins)
51
, Dunaliella salina (natural source of β-carotene)46,57, Haematococcus 
pluvialis (production of astaxanthin)
46,57
, Porphyridium cruentum ( production of sulphated 
polysaccharides, phycocyanin, and phycoerithrin)
49,51
, Phaeodactylum tricornutum 
(production of eicosapentaenoic acid)
58
, etc.  
A reason behind this small number of commercialized microalgae species is a complex 
process of growth optimization of these organisms and in obtaining the compound of interest 
in large quantities. The chemical composition of microalgae is not an intrinsically constant 
factor, it varies among strains and batch cultures, seasons, and it is affected by environmental 
and culture conditions (temperature, pH, mineral content of water, light exposure, and 
agitation). Therefore, it is very important to select adequate culturing methods (e.g. open or 
closed photobioreactors, indoors or outdoors) with carefully controlled conditions, so that the 
metabolism of the microalgae favours a high production of the particular compound of 
commercial interest (e.g. PUFAs antioxidants, polysaccharides)
46,50,51
. Once the biomass is 
enriched in the target compound, the next step is to optimize the conditions to extract the 
valuable component with high yields while maintaining its activity. An efficient separation 
process of the desired compound should be able to process a large volume of biomass, yield a 
product with a high dry weight percentage, and require modest investment, low consumption 
of energy, and low maintenance cost
46,50,51
.  
Another difficulty in the production of microalgae is their recovery and preservation. The low 
productivity of biomass means that recovery systems need to efficiently manage very large 
volumes of medium with a very low concentration of biomass. This alone constitutes a great 
challenge to engineers who need to combine various recovery operations such as 
sedimentation, flotation, filtration, or centrifugation to recover and then preserve (freeze-
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drying or spray-drying)  the microalgae cells produced, so as to maintain the quality of the 
biomass and the activity of compounds of interest
49–51
.   
 
1.4.2. Microalgae used in this study to assess cytotoxicty 
In this study, ethyl acetate and ethanol extracts of six microalgal species were selected to be 
screened for cytotoxicity in cancer cell lines: Nannochloropsis sp., Isochrysis sp., 
Skeletonema costatum, Porphyridium sp., Tetraselmis sp. CTP4, and Phaeodactylum 
tricornutum. In literature, up to date, there are no reported cytotoxicity assays that involve 
testing ethyl acetate extracts of these species on both HepG2 and THP-1 cells. For example, 
previous studies from MarBiotech research group reported toxicity of acetone, hexane, water 
and diethyl ether extracts of Isochrysis galbana on HepG2 cells, but research did not involve 
ethyl acetate extract and THP-1 cells
55
. In another study, a sulfoglycolipidic fraction (SF) 
isolated from Porphyridium cruentum was screened for anti-proliferative activity on human 
breast adenocarcinoma (MCF-7), human prostate adenocarcinoma (PC-3), and human 
malignant melanoma (M4) Beu cell-lines
59
. No studies are available reporting anti-
proliferative activity of this microalgae on HepG2 and THP1. Sulphated polysaccharides 
extracted in ethanol from Phaeodactylum tricornutum, showed strong anticancer activity on 
HepG2 cells, but not on THP-1 cells
60
. Also, Phaeodactylum tricornutum methanol extract 
was toxic to human promyelocytic leukemia cell line (HL60), while Nannochloropsis oculata 
methanol extracts were toxic to human chronic myeloid leukemia cell line (K562)
61
. As for 
Skeletonema costatum, organic extract of this diatom was studied in vitro for its effect on 
asynchronous cells of a human non-small-cell bronchopulmonary carcinoma line (NSCLC-
N6) and showed inhibition of growth in G1 stage of cell cycle
62
(Table 6). To the extent of our 
knowledge, Tetraselmis sp. CTP4 was not assessed for cytotoxic activity so far. Based on all 
stated above, we decided to screen for cytotoxic effects of ethyl acetate and ethanol extracts 
of already explained microalgal species on HepG2 and THP-1 cancer cells. 
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1.5. Objectives  
 
The objective of this thesis is to search for innovative drug leads for hepatocellular 
carcinoma and acute monocytic leukaemia treatment. For this purpose, different extracts 
(ethanol, ethyl acetate) from already commercialized, available microalgal biomass 
(Porphyridium sp., Skeletonema costatum, Nannochloropsis sp., Phaeodactylum 
tricornutum, Tetraselmis sp. CTP4 and Isochrysis sp.) were screened for cytotoxicity on 
HepG2 and THP-1 tumoural cell lines. In addition, a cell line (S-17) derived from a 
murine bone marrow (non-tumoural) was used to assess selectivity. Results were 
compared with etoposide, a widely used agent in chemotherapy. 
 
In order to study the anti-tumoural effect of microalgae extracts on HepG2 and THP-1 
cells and propose a new anticancer drug lead, we have established the following specific 
objectives: 
1. To test different concentrations of ethanol and ethyl acetate extracts from 
microalgae (Porphyridium sp., Skeletonema costatum, Nannochloropsis sp., 
Phaeodactylum tricornutum, Tetraselmis sp. CTP4 and Isochrysis sp.) on HepG2 
and THP-1 cell lines in order to determine the effects on cell viability. 
2. To test different concentrations of ethanol and ethyl acetate extracts on S-17 non-
tumoural cell line to assess selectivity. 
3. To fractionate the most active extracts and produce active fractions with a more 
limited number of compounds. 
4. To chemically characterize the most active fraction and tentatively identify a 
potential drug lead in microalgae extracts/fractions. 
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2. MATERIALS AND METHODS 
 
2.1. Chemicals and reagents 
Solvents needed for extraction, fractionation and derivatization: hexane, ethyl acetate (EA), 
ethanol (ETH), dichloromethane (DCM), methanol (metOH), acetyl chloride and dimethyl 
sulfoxide (DMSO), were all analytical grade and purchased from VWR International (Leuven, 
Belgium). Ultrapure, Type 1 water was obtained using a MilliQ® Water Purification System 
(Darmstadt, Germany). For characterization by gas chromatography – mass spectrometry 
(GC/MS), n-hexane GC analysis grade was used (VWR International (Leuven, Belgium). 
Dulbecco's Modified Eagle's medium (DMEM), foetal bovine serum (FBS), L-glutamine (200 
mM), penicillin/streptomycin mixture (10,000 U), trypsin/EDTA solution (10x), phosphate 
buffer saline (PBS) (10X) were obtained from Lonza Ibérica (Barcelona, Spain).  
Roswell Park Memorial Institute medium (RPMI-1640) was from Thermo Fischer Scientific.  
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)(ultrapure grade) was 
obtained from VWR International (Leuven, Belgium). Etoposide (synthetic, 98-105%, 
powder) was purchased from Sigma-Aldrich (Steinheim, Germany).  
 
2.1.1. Algal biomass 
Algal biomass was kindly provided by NECTON S.A. (Olhão, Portugal), a company 
specialized in the cultivation and commercialization of microalgae in Portugal since 1996. 
Biomass was dried, in the form of a powder, stored at room temperature and protected from 
light and humidity before conducting experiments. 
 
2.2. Preparation of the extracts 
Powdered (dry) biomass was mixed with the selected solvent (water, ethanol or ethyl acetate) 
(1:40, w/v) and left overnight (12-15 h) under continuous stirring, at room temperature (RT, 
20°C). Next morning, samples were centrifuged (2500 rpm, 5 min, RT), supernatants 
recovered and filtered with qualitative, medium flow rate filter paper (10-12 µm pore size; 
Prat Dumas, France). The process was repeated three times. Finally, supernatants were 
combined and vacuum-filtered, using 0.45 µm and 0.2 µm filters (Prat Dumas, France) 
sequentially. Extracts were then dried using a rotary evaporator (Figure 3; IKA, Staufen, 
Germany) at 40°C under reduced pressure (Table 7). Once the solvents were completely 
evaporated, extracts were dissolved in dimethyl sulfoxide (DMSO) to a final concentration of 
20 mg/mL and stored at -20°C. 
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Ethyl acetate was selected due to its medium polarity, low toxicity and environmentally 
friendly properties. In addition, this solvent is acceptable for food applications
63
. Its medium 
polarity (polarity index = 4.4)
64
 allows for the extraction of both polar (sulphated 
polysaccharides, polyphenols, vitamins B and C and phycobiliproteins) and non-polar 
(chlorophylls, carotenoids and polyunsaturated fatty acids - PUFAs -, α-tocopherol - vitamin 
E - and vitamin A)
65
 components from marine microalgae biomass in order to assess their 
bioactivity. Moreover, it has been reported that ethyl acetate extracts showed high 
cytotoxicity for cancer cells lines, while no effect was observed on healthy cell strains
56,66
.  
Ethanol was chosen because of its slightly higher polarity index (5.5)
61
.
 
It was expected that 
ethanol would extract more polar compounds but also responsible for antioxidant and anti-
proliferative activities (polyphenolics, vitamins and some carotenoids). In addition, ethanol 
extracts are easier to fractionate than ethyl acetate and even more environment friendly. 
 
      
Figure 3. Extract preparation from dried algal biomass. Powder was mixed with solvent and left overnight 
under constant stirring. Next day the mixture was first centrifuged and filtered (A) and afterwards concentrated 
in a rotary evaporator (B). 
2.3. Selection of extracts for testing 
 
The microalgal extracts (ethanol, ethyl acetate) tested on HepG2 and THP-1 cell lines were 
selected based on bibliographic research about their reported cytotoxicity on these cell lines 
and their immediate availability (commercialized species).  
At first only ethyl acetate and then ethanol extracts of the following microalgae were selected: 
Porphyridium sp., Skeletonema costatum, Nannochloropsis sp., Phaeodactylum tricornutum, 
Tetraselmis sp. CTP4 and Isochrysis sp. 
A
 B  
B 
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Figure 4.Microalgae species used to test cytotoxicty on HepG2 and THP-1 cells. Isochrysis galbana (A) 
(Source:www.algaeresearchsupply.com); Nannochloropsis oculata (B) (source: www.cfb.unh.edu); 
Porphyridium cruentum (C) (source: www.algaeresearchsupply.com); Skeletonema spp. (D) (source: 
www.cfb.unh.edu ); Tetraselmis sp. CTP4 (E) (source: Pereira et al, 2015); Phaeodactylum tricornutum (F) 
(source: www.utex.org ).  
2.4. Bioassays  
2.4.1. Cell cultures 
 
Cancer cell lines were selected based on their immediate availability and opposed 
morphology, having HepG2 as epithelial and THP-1 as monocytic cell line. HepG2 is an 
adherent cell culture, representative of solid tumours (hepatocellular carcinoma), and THP-1 
cells in suspension, representative of bone marrow malignancies (acute monocytic 
leukaemia). S17 cells are adherent cells, derived from murine bone marrow and were used as 
healthy control and to assess selectivity of extracts.  
The human hepatocellular carcinoma cell line HepG2 (ATCC® HB-8065
TM
) and human 
monocytic cell line THP-1 (ATCC® TB-202) were maintained in RPMI-1640 culture media 
supplemented with 10 % foetal bovine serum (FBS), L-glutamine (2mM), penicillin (50 
U/mL) and streptomycin(50 μg/mL). S17 cell line was kindly provided by Dr. Nuno Santos 
B A C 
D E F 
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(CBMR, UAlg) and grown in DMEM culture media supplemented with 10 % FBS, L-
glutamine (2 mM), penicillin (50 U/mL) and streptomycin (50 μg/mL). All cell lines were 
grown at 37°C and 5.0% CO2 in humidified atmosphere (Binder, Tuttlingen, Germany).  
 
2.4.2. In vitro cytotoxic activity  
2.4.2.1. MTT assay 
In vitro cytotoxic activity of crude ethanol and ethyl acetate extracts was assessed by the 
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) colorimetric assay. 
It is a rapid, quantitative assessment of cell proliferation which measures mitochondrial 
dehydrogenase performance
67
. During the test, yellow water-soluble MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide, a tetrazole), is reduced to purple 
formazan due to cleavage of the tetrazole ring by dehydrogenases present in the mitochondria 
of living cells. This reduction takes place only when mitochondrial reductase enzymes are 
active. Resulting formazan crystals are soluble in dimethyl sulfoxide (DMSO) and other 
organic solvents, but are insoluble in water. Therefore, the amount of crystals formed has a 
positive correlation to the number of live cells. This can be quantified by measuring the 
absorbance (optical density), between 500 and 600 nm. This method has certain limitations 
since it is influenced by the physiological state of cells and there is some variance in 
mitochondrial dehydrogenase activity between different cell types. Nevertheless, the MTT 
assay has long been used as the “golden standard” of cytotoxicity assays as it is highly 
sensitive and has been miniaturised for use as a high-throughput screening assay
67,68
. 
The assay is recommended even in ISO Standard for assessing cytotoxicity (ISO 10993-5: 
Biological Evaluation of Medical Devices), where in Annex C, the MTT assay is prescribed 
as a quantitative cytotoxicity method. The MTT assay has several benefits over traditional 
qualitative cytotoxicity methods: it can detect as few as 950 cells, has high repeatability and a 
standard microplate reader can be used to analyse the results, increasing its throughput 
ability
69
. 
For the purpose of this Master thesis, a short MTT assay (48h of exposure) was performed 
and consisted of the following steps. On the first day, exponentially growing cells were 
seeded on 96-well plates at a density of 5 × 10
3
cells/well for adherent cell lines (HepG2 and 
S-17) and 1 × 10
4
  cells/well for the suspension cell line (THP-1). Cell suspension for plating 
cells was prepared in the following manner: one flask of each adherent cell line (HepG2, S-
17) was first trypsinised adding 1 mL of trypsin/EDTA solution and incubated at 37°C in 
5.0% CO2 for 10 minutes or until cells were completely detached from the bottom. 
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Afterwards, 3 mL of corresponding culture media was added to the flasks to inactivate 
trypsin, suspension was gently mixed, and 0.5 mL was transferred to Eppendorf tubes for 
counting. Then, 10µL was taken and mixed with 0.4 % trypan blue (1:1, v/v) and 10µL was 
applied to the counting chamber. Cells were counted under a 10× objective using an inverted 
microscope (Motic, Germany). Procedure for THP-1 cells was the same, without the 
trypsinization step, as it is not required for cells in suspension. After counting, cells were 
plated and incubated overnight at 37°C in 5.0% CO2, to recover and to attach to the bottom of 
the well (for adherent cell lines). On the second day, the extracts were applied at 
concentrations ranging from 125 to 3.9 µg/mL and incubated for 48h at 37°C in 5.0% CO2 
(Figure5). A positive control was done in which cells were treated for 48 h with etoposide at 
the same concentrations of the extracts and negative control cells were left untreated. In 
addition, dimethyl sulfoxide (DMSO) was tested for toxicity as extracts were dissolved in 
DMSO in order to apply to cells. For this purpose, one group of control cells was treated with 
DMSO only, at the highest concentration used in the test wells (0.6 %, v/v). On the fourth 
day, two hours before the end of the incubation period, 20µL of MTT (5 mg/mL in PBS) were 
added to each well and further incubated for 2h at 37°C in 5.0% CO2 (Figure 5). A blank was 
performed consisting only of complete culture medium and MTT. After the incubation, the 
medium was carefully removed from the wells and purple formazan crystals were in 150 µL 
of DMSO (Figure 5). Then, absorbance was measured on a Biotek Synergy 4 
spectrophotometer (Winooski, US) at 590 nm.  
Cell cultures were handled under Class II Biological Cabinet (Telstar, Terrassa, Spain), 
applying aseptic technique and using sterile pipette tips, solutions and tubes. 
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Figure 5. MTT assay performed on a 96-well plate (HepG2 cell line). Cells were plated and treated with extracts 
for 48h (A). After incubation, MTT was added and insoluble formazan crystals were formed (B). To dissolve the 
crystals, DMSO was added and plates were read at 590 nm. C – negative control (untreated cells); DMSO – cells 
treated with dimethyl sulfoxide (DMSO); POC, PHA, N, ISO, SK, CTP4 – cells treated with microalgal extracts; ET 
– cells treated with etoposide. Extracts were applied in decreasing concentration, starting with 125.0 µg/mL in the 
first well and ending with 3.9 µg/mL in the last well of each column. 
 
 
2.4.2.2. Calculations and data interpretation 
 
Results of MTT assay were expressed as percentage of cell viability in respect to untreated 
cells (controls) and as half maximal inhibitory concentration (IC50, µg/mL).  
 
In order to calculate the volume of cell suspension needed to seed appropriate amount of cells, 
Neubauer chamber  was used for counting (VWR International, Leuven, Belgium) (Figure 6) 
following the equation: 
 
where N represents number of cells/mL;  A, B, C, and D (Fig. 6) correspond to the number of 
cells in each quadrant of the counting chamber and 10
4
 is a conversion factor
70
. 
To calculate cell viability (%) after the treatment, the average absorbance of blank wells was 
calculated first and then subtracted from all the measurements on the 96-well plate, to 
eliminate the background noise. Afterwards, average of negative control wells (cells without 
treatment) was calculated representing 100 % of cell viability.  
A B C 
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The cell viability of the positive control, DMSO control and cells treated with the extracts was 
then calculated following the formula:  
 
 
where A states for absorbance values at 590 nm.  
Obtained values were then analysed using the GraphPad Prism software to obtain half 
maximal inhibitory concentration (IC50). A dose-response curve by means of non-linear 
regression (variable slope, four parameters) was plotted to obtain IC50 (µg/mL) values. All 
experiments were conducted at least three times with all conditions performed in triplicates. 
Only IC50 values below 100 µg/mL and acceptable 95% confidence interval (CI) were 
selected. 
In addition, selectivity index (SI) of the extracts was determined using the equation: 
 
  
where CNT and CT correspond to the extract-induced cytotoxicity on non-tumour cells (S-17) 
and tumour (HepG2 and THP-1) cells, respectively
48,55,71,72
. 
 
  
Figure 6.  Neubauer counting chamber. Average count of the cells in red marked squares multiplied by 10000 
gives number of cells per mL (A) (source: www.biocyclopedia.com; www.vwr.com) 
 
A 
B 
C 
D 
A B 
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2.5.  Extract fractionation 
The active crude ethanol extract of Phaeodactylum tricornutum was subjected to a bio-guided 
fractionation procedure in order to concentrate the active (lead) compound responsible for 
cytotoxic activity. Liquid-liquid extraction (LLE) was chosen as a preference method over 
silica gel column chromatography for this purpose, firstly because column chromatography 
can be time- and solvent-consuming while LLE can be performed in one day and reduces the 
volume of solvent spent; secondly, with LLE only four fractions were obtained, hence 
decreasing the amount of fractions to be further tested for cytotoxic activity. 
Liquid-liquid extraction, also known as partitioning, is a process of separation of a solute 
(compound) between two immiscible solvents, in a biphasic system. One of the solvents is 
usually water or the aqueous phase and the other solvent is a non-polar, organic phase. The 
extraction is performed in a separating funnel and comprises a step of gentle mixing of the 
two solvents, followed by a step of phase separation. It is important to consider both steps in 
the selection of solvents and modes of operation. Equilibrium is reached when the chemical 
potential of the extractable solute is the same in the two phases. Position of the phases in the 
separating funnel depends on the density of the solvents. The aqueous phase is usually on the 
bottom as water is more dense than most organic solvents
73
. During LLE, aqueous layer was 
successively extracted with organic solvents of increasing polarity (e.g. n-hexane – 
chloroform – ethyl acetate)74,75. 
For the LLE, the crude ethanol extract of Phaeodactylum tricornutum (3.5 g) was dissolved in 
ethanol, introduced in the separating funnel and mixed with MilliQ water (1:4, v/v) to 
increase the polarity of the mixture making it relatively immiscible with the organic solvents 
selected. Then, 50 mL of hexane was added to the mixture; the funnel was gently mixed and 
left to sit until two phases formed. The organic, hexane layer was collected while aqueous 
layer was introduced again to the funnel and extracted with another two portions of hexane. 
The process was repeated with dichloromethane and finally ethyl acetate, affording four 
fractions (hexane fraction, dichloromethane fraction, ethyl acetate fraction and remaining, 
water-ethanol fraction) (Figure7). Organic fractions were concentrated using a rotary 
evaporator (40°C) under reduced pressure (Table 7), transferred to pre-weighed vials and 
dried under a gentle nitrogen flow to determine the yield of the fraction. Fractions were then 
dissolved in dimethyl sulfoxide (DMSO) to a final concentration of 20 mg/mL. Water-ethanol 
fraction was freeze-dried and also stored dissolved in DMSO at a concentration of 20 mg/mL.  
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The four fractions obtained (hexane, dichloromethane, ethyl acetate and water-ethanol) were 
retested for cytotoxicity and selectivity on HepG2, THP-1 and S-17 cell lines, as described 
above. The most active fraction was chemically characterised by gas chromatography – mass 
spectrometry (GC/MS) to tentatively identify major compounds present and possibly 
responsible for the observed cytotoxicity. 
 
2.5.1. Determination of extract yield 
The yield of each fraction was expressed as percentage (%) in respect to initial mass of the 
extract subjected to fractionation (3.5 g) and calculated from the following formula:  
 
 
where m1 (g) corresponds to the weight of the extract residue after solvent removal; m2 (g) is 
weight of the dry biomass.  
 
  Table 7.  Properties of organic solvents used for LLE and operating conditions for rotary evaporator
76,61
 
Solvent Formula Molar 
mass 
(g/mol) 
Evaporation 
energy (J/g) 
Boiling 
point at 
1013 
mbar 
Density 
(g/cm
3
) 
at 20°C 
Pressure 
 (mbar)  
Polarity 
index 
Ethanol C2H6O 46.0 879 79 0.789 175 5.1 
Water H2O 18.0 2261 100 0.998 75 9.0 
Hexane C6H14 86.2 368 69 0.659 360 0.0 
Dichloromethane CH2Cl2 84.9 251 39.8 1.325 850 3.1 
Ethyl acetate C4H8O2 88.1 394 77 0.895 240 4.4 
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2.6. Characterization with gas chromatography – mas spectrometry (GC/MS) 
2.6.1. Derivatization of samples 
Prior to GC/MS analysis, derivatization was needed to increase the volatility of compounds 
and improve separation of analytes. This was achieved by adding acetyl chloride (catalyst) 
and methanol.  
Dried fraction (5mg) was treated with 1.5 mL of derivatization solution (methanol/acetyl 
chloride, 20:1, v/v), in reaction vessels. Afterwards 1 mL of hexane was added, and the 
mixture was placed in a water bath for 1 hour at 70°C. After cooling in an ice bath (15 min), a 
mixture of distilled water and n-hexane was added (1:4, v/v), and the mixture centrifuged 
(2000g, 5 min, RT). The organic phase was collected, and the whole step was repeated one 
more time. Finally, the organic phase was removed, dried with anhydrous sodium sulphate 
    
Figure 7. Liquid-liquid extraction (LLE) of Phaeodactylum tricornutum ethanol extract. During the LLE, solvents 
with increasing polarity were used. Dried extract was first dissolved in ethanol and mixed with Milli Q water in a 
separating funnel (A). Next, hexane was added, funnel was gently shaken and two phases were formed; organic (hexane) 
fraction in the upper part and aqueous fraction (water and ethanol) in the lower part due to the water density (Table 8) (B). 
Afterwards, aqueous fraction was introduced again into the funnel and extracted with dichloromethane, which has higher 
density than water (Table 8) and went to the bottom, while aqueous fraction formed upper layer (C). Last extraction of 
aqueous phase was done with ethyl acetate, affording two fractions, organic (ethyl acetate) in the upper layer and water 
with ethanol in the lower layer (D). Each extraction was repeated three times. 
 
A B C D 
Hexane 
H2O 
H2O 
Dichlorometane 
H2O 
Ethyl acetate 
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and filtered (0.22 μm). Hexane was evaporated under a gentle nitrogen flow until dryness and 
the fraction resuspended in 500 μl of GC-grade hexane and transferred to vials for GC-MS 
analysis
77
. 
2.6.2. GC/MS analysis 
Samples were analysed on an Agilent GC-MS (Agilent Technologies 6890 Network GC 
System) coupled with MS detector (5973 Inert Mass Selective Detector) equipped with a 
DB5-MS capillary column (25 m × 0.25 mm internal diameter, 0.25 μm film thickness, 
Agilent Tech) using helium as carrier gas. Samples were injected at 300 °C and the 
temperature profile of the GC oven was 60 °C (1 min), 30 °C min−1 to 120 °C, 5 °C min−1 to 
250 °C, and 20 °C min−1 to 300 °C (2 min). For the identification and quantification of 
bioactive compounds in fractions, the total ion mode was used. 
 
2.6.2.1. Expression of results 
In order to identify the compounds present in the active extract, Bruker MSWS Software was 
used with integrated National Institute Standard and Technology (NIST) library. Components’ 
relative percentages were calculated based on GC peak areas in respect to total area of peaks.  
 
2.7. Statistical analysis 
Results were expressed as mean ± standard deviation, and all experiments were conducted at 
least three times, and performed in triplicates. Significant differences were assessed by 
analysis of variance (ANOVA) using GraphPad Prism v. 5.0 (GraphPad Software, Inc., La 
Jolla, CA, USA). Differences were considered as statistically significant when p < 0.05. 
Significance between means was analysed by Dunnett’s and Tukey’s multiple comparison 
tests. Prior to ANOVA, D'Agostino-Pearson test was performed to check for normality of data 
and homogeneity of variances was assessed with unpaired t-test. The 50% inhibitory 
concentrations (IC50) were calculated by sigmoidal fitting of the data (dose-response curve) in 
the GraphPad Prism v. 7.0 program.  
 
36 
 
3. RESULTS AND DISCUSSION 
3.1. Initial screening for cytotoxicity against HepG2 and S17 cell lines –  
ethyl acetate (EA) extracts 
 
In the initial screening, the cytotoxicity of ethyl acetate (EA) extracts from Phaeodacytlum 
tricornutum (PHA), Porphyridium sp.(POC), Isochrysis sp. (ISO), Skeletonema costatum 
(SKLT), Nannochloropsis sp.(NANNO) and Tetraselmis sp.CTP4 (T CTP4) was assessed 
against human hepatocelluar carcinoma cell line (HepG2) and murine bone marrow cells 
(S17) (non-tumoural) via 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
tetrazolium (MTT) reduction assay for 48h. Etoposide, which is used in the treatment of 
different types of cancer and acts as topoisomerase II inhibitor
36–38
 was used as positive 
control in this study. All extracts, including etoposide, were applied to cells in a range of 
concentrations from 3.9 µg/mL to 125 µg/mL. In addition, dimethyl-sulfoxide (DMSO) was 
tested for cytotoxicity and applied at highest concentration used in test wells (0.6%, v/v). As 
all the extracts were dissolved in DMSO prior the experiment, it was necessary to show that 
this solvent is not toxic to cells at concentrations used.  
Results of average cell viability expressed as percentage in respect to untreated controls are 
summarised in Annex 1. All extracts, except NANNO and T CTP4, led to a reduction in cell 
viability in a concentration-dependent manner. The best results were achieved with the 
application of PHA, POC, SKLT and ISO,where cell viability of HepG2 cells in respect to 
untreated controls at 125 µg/mL was reduced to 6.44%, 14.2, 4.88 and 4.92%, respectively. In 
the case of the non-tumoural cell line (S17), the same extracts (PHA, POC, SKLT, ISO) 
showed less cytotoxicity at the same concentration with cell viabilites of 39.9%, 81.6%, 33.7 
and 40.6 %, respectively. This could indicate that some of the extracts showed higher 
selectivity towards cancer (HepG2) cells. It was also observed that all extracts lost their 
cytotoxic activity below the 31.25 µg/mL concentration. DMSO showed no toxicity to the 
cells with average cell viability of 94.9% for HepG2 and 91.6% for S17 cell line, which is 
statistically similar to that of untreated controls. Due to its medium polarity, DMSO is the 
prefered solvent in cytotoxicity assays for wide range of compounds, as it can dissolve both 
polar and nonpolar compounds; in addition, it is miscible with water
78
. Therefore, it is 
important to determine the safe concentration that could be used in the assay, as response 
greatly depends on the type of cell line used. For example, for skin fibroblast cells, DMSO 
concentration must not exceed 0.1% final concentration (v/v)
79
. On the other hand, study with 
Caco2/TC7 colon tumor cell line showed that even at 10% (v/v) DMSO did not induce 
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cytotoxicity
78
. Here, we showed that for HepG2 and S17 cell lines, DMSO at final 
concentration of 0.6 % (v/v) did not induce any observable toxic effect. 
Next step in this study was to calculate the half-maximal inhibitory concentration, IC50 
(µg/mL). The IC50 is a measure of the effectiveness of a substance in inhibiting a specific 
biological or biochemical function
52
. In this particular case, it represents the concentration of 
a drug (extract) that will cause 50% decrease in cell viability in vitro. So, the most active 
extract is the one with the lowest IC50  value. Based on the IC50 results, the most active extract 
was identified in terms of bioactivity, and selectivity of  extracts was assessed (Table 8). In 
that sense, the most active extract will be the one with the lowest IC50  value. At this step, two 
extracts, NANNO and T CTP4, were excluded from further analysis – as the decrease in cell 
viability of HepG2 cells was less than 50% at all concentrations tested (Figure 8). 
The most active extract was the one prepared from P. tricornutum (PHA) with the IC50 value 
of 34.6±3.5 µg/mL for HepG2 cells. This value was similar to that of etoposide (IC50 = 
29.0±3.2 µg/mL) which is a widely used chemotherapeutic agent. Selectivity between 
tumoural and non-tumoural cells (S17) was used to assess the effectiveness of the extracts in 
cancer therapies
80
. This means that promising candidate for anti-cancer therapy needs to be 
highly selective for cancer cells while maintaining healthy cells, as opposed to 
chemotherapeutics, which are known for low selectivity, that causes some serious secondary 
effects
36
. As shown in Table 8, etoposide displayed low selectivity (SI=1.56), which was 
expected.  
In comparison to S17 cells, PHA showed high selectivity (SI=3.09). Similar result was 
obtained with Skeletonema sp. with calculated IC50 of 37.2 ±3.6 µg/mL, which was also 
comparable to etoposide. However, in this case, the extract showed no selectivity when 
compared to S17 cells (IC50 = 34.8 ± 5.4 µg/mL), meaning that it was highly toxic even for 
healthy cells, and it was therefore excluded from further evaluation. Extracts obtained from 
Porphyridium sp. (POC) and Isochrysis sp. (ISO) had slightly lower cytotoxicity against 
HepG2 cells with IC50 values of 42.3 ±2.7  and 44.7 ± 3.1 µg/mL, respectively. ISO extract 
displayed low selectivity (SI=1.77) similarly to that one of etoposide (SI=1.56). Interestingly, 
cytotoxicity of etoposide on HepG2 cell line was much lower than previously reported by 
Vizetto-Duarte et al. (2016) for the same cell line and under same working conditions. This 
could be due to the development of resistance of HepG2 cells to etoposide over the course of 
time. These cells are known to display greater resistance to drugs in general, comparing to 
other cell lines
25,48
; hence the reason for choosing this cell line for screening of promising 
compounds in this study. It is noteworthy to mention that development of etoposide resistance 
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is quite frequent after prolonged exposure of cell lines to this drug which represents also a big 
problem when treating patients with ovarian or lung cancer using this chemotherapeutic 
agent
81,82
. 
According to the previously established criteria of National Cancer Institute (NCI) in 1990, 
natural extracts are considered as promising candidates for anticancer drugs when the IC50 is 
less than 30 µg/mL and selectivity index higher than 3
83
. Unfortunately, none of the extracts 
displayed IC50 below the established criteria, but PHA extract had the IC50 closest to this value 
and more importantly, showed high selectivity compared to non-tumoural cell line. Previous 
studies on MDA-MB-231 breast cancer cells reported cytotoxicity of C. calcitrans ethyl 
acetate (EA) extracts with the IC50 of 60 µg/mL after 72 h of exposure.
56
. Moreover, EA  
extracts obtained from some plants (Rhaponticum uniflorum) were successful in an inhibition 
of cell growth and induction of apoptosis in oral squamous cell carcinoma cell line SSCC15 
with reported IC50 value of 50µg/mL
84
. Taking into account that both of these cell lines are 
adherent like HepG2 used in this study, results obtained with PHA extracts (IC50 = 34.6±3.5  
µg/mL) could be considered as promising. Therefore, it was decided to proceed with this 
extract in further studies. 
39 
 
 
 
 
 
 
Figure 8.  Cell viability (%) after 48 h 
exposure to different concentrations (3.9 – 
125 µg/mL) of the ethyl acetate (EA) 
extracts of the species  P. tricornutum, 
Isochrysis sp., Porphyridium sp., Skeletonema 
costatum, Nannochloropsis sp., and 
Tetraselmis sp. CTP4) and etoposide, on 
HepG2 and S17 cell lines 
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Table 8. In vitro cytotoxic activity (IC50; µg/mL) of the ethyl acetate (EA) extracts of the species P. 
tricornutum, Isochrysis sp., Porphyridium sp., Skeletonema costatum, Nannochloropsis sp., Tetraselmis sp. 
CTP4 and etoposide, on HepG2 and S17 cell lines 
Species  Cell line  
  
HepG2 S17 Selectivity 
index 
P. tricornutum (PHA) 34.6±3.5
a,b,A
 107±7
c,B
 3.09±0.12
b
 
 
Porphyridium sp. (POC) 42.3±2.7
b,A
 >125
a,B
 >2.7c 
Isochrysis sp.(ISO) 44.7±3.1
b,A
 79.2±2.7
b,B
 1.77±0.09
a
 
 
Skeletonema costatum SKLT) 37.2±3.6
a,b,A
 34.8±5.4
a,A
 n.s 
Nannochloropsis sp. (NANNO) >125 >125 n. s 
Tetraselmis sp. CTP4 (T CTP4) >125 >125 n. s 
Etoposide 29.0±3.2
a,A
 45.4±0.5
a,B
 1.56±0.11
a
 
Results are expressed as mean ± SD of data obtained from 3 different experiments performed in 
triplicates. Significant differences (p<0.05) were assessed with Tukey’s test. Different letters 
(a,b,c) within each column represent significant differences between the species and species vs. 
etoposide for each cell line. Different letters (A,B,C) within each row represent significant 
differences between the effect of the extracts to the different cell lines; n. s – non-selective (SI=1). 
 
 
3.2. Screening for cytotoxicity of P. tricornutum (PHA) ethanol extract against 
HepG2 and S17 cell lines 
 
In the first part of the screening for cytotoxic activity of the ethyl acetate (EA) extracts from 
different microalgae species, PHA extract was identified as the one with highest bioactivity in 
terms of IC50 value and selectivity comapring to non-cancer cells (IC50 = 34.6±3.5 µg/mL; 
3.09, respectively). In the next step, the ethanol extract from the same species (P. 
tricornutum) was tested for cytotoxicity against HepG2 and S17 cell lines to assess cell 
viability and selectivity, in order to compare with EA extract and determine which of them 
exhibits lower IC50.  
As it was explained in the Material and methods section, the ethyl acetate (EA) extracts were 
selected in the first screening phase to assess bioactivity on cancer cells, due to the medium 
polarity of EA, which allows for the extraction of both polar (sulphated polysaccharides, 
polyphenols, vitamins B and C and phycobiliproteins) and non-polar (chlorophylls, 
carotenoids and polyunsaturated fatty acids (PUFA’s), α-tocopherol (vitamin-E) and vitamin-
A
65
 components from marine microalgae biomass to assess their bioactivity on cancer cell 
lines. Another reson for chosing this solvent was based on previous studies from MarBiotech 
research group dealing with cytotoxicity of microalgae extracts. It was  revealed that less 
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polar extracts (e.g. acetone, ether, hexane) from Isochrysis galbana, Tetraselmis sp., and 
Scenedesmus sp., were more toxic to HepG2 cells than more polar ones. In fact, the best result 
was achieved with the least polar hexane extract of Tetraselmis sp., which reduced cell 
viability down to 10.8%, similar to etoposide
55
..  
Apart from its wide usage in pharmaceutical industry
85
, EA is present in confectionery for 
flavoring ice creams and cakes, and perfumes, as well as fruits such as apples
56
. However, it 
was decided to test ethanol extract of the same species to check if it would show higher 
bioactivity to cancer cells. Ethanol has a slightly higher polarity index (5.5)
61
 than EA, and it 
was expected that ethanol would extract more polar compounds,  also known for anti-
proliferative activities (polyphenolics, vitamins and some carotenoids) and lead to lower IC50 
values for HepG2 cells. In addition, the Isochrysis sp. ethanol extract was tested due to the 
previously reported cytotoxicity of this species against HepG2 cell line
55
, as well as due to the 
medium cytotoxicity displayed (IC50 = 44.7±3.1µg/mL) with EA extract; therefore it was 
investigated whether ethanol could extract more bioactive compounds from the biomass of 
this species. After 48h of exposure to P. tricornutum ethanol extract (PHA ETH), a 
significantly lower IC50 was obtained (19.4 ±2.2µg/mL) for HepG2 cells comparing to the 
previous assay done with P. tricornutum ethyl acetate (PHA EA; 34.6 ± 3.5µg/mL). This 
value was again similar to that of etoposide (positive control used in this study). Furthermore, 
the selectivity index was higher in the case of PHA ETH (SI=4.40) comparing to PHA EA 
(SI=3.09) (Table 9). Looking at the cell viability results (Annex 2; Figure 9), at concentration 
of 31.2µg/mL only 20.8 % of HepG2 cells survived, which is less than in the previous 
experiment with PHA EA where at the same concentration the survival rate was more than 
50%. For S17 cells, PHA ETH showed higher toxicity than PHA EA with an IC50 of 85.6 ±4.4 
µg/mL compared to PHA EA (IC50 = 107±7 µg/mL) (Table 9). This difference can be 
attributed to the potent activity of the extract at 125µg/mL, where only 8.08% of cells 
survived the exposure to PHA ETH, while this number went up to 39.9 % in the case of PHA 
EA (Annex 2; Figure 9).  
With Isochrysis sp. ethanol extract (ISO ETH) poor results were obtained with IC50 value of 
67.8± 2.6 µg/mL for HepG2 cells, which was significantly higher than the previous result 
from ISO EA (IC50 = 44.7±3.1 µg/mL). Moreover, ISO ETH displayed low selectivity (SI= 
1.53) similarly to that of etoposide (SI=1.61). Due to these results, both ISO EA and ISO ETH 
were excluded from further experiments. 
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Figure 9. Cell viability (%) after 48 h exposure to different concentrations (3.9 – 125 µg/mL) of the ethanol 
(ETH) extracts of the species P. tricornutum and Isochrysis sp., on HepG2 and S17 cells. 
 
 
Table 9. In vitro cytotoxic activity (IC50; µg/mL) of ethanol (ETH) extracts of P. tricornutum, 
Isochrysis sp. and etoposide on HepG2 and S17 cell lines 
 
 
 
 
 
 
 
 
 
 
 
Species  Cell line Selectivity 
  HepG2 S17 HepG2vs.S17 
P. tricornutum ETH 19.4±2.2
a,A
 85.6±4.4
a,B
 4.40±0.15
b
 
Isochrysis sp ETH 67.8±2.6
c,A
 104±4
b,B
 1.53±0.08
a
 
P. tricornutum  EA 34.6±3.5
a,b,A
 107±7
b,A
 3.09±0.12
c
 
Isochrysis sp EA 44.7±3.1
b,d,A
 79.2±2.7
a,B
 1.77±0.09
a
 
Etoposide 29.0±3.2
a,A
 45.4±0.5
c,B
 1.56±0.11
a
 
Results are expressed as mean ± SD of data obtained from 3 different experiments performed in 
triplicates. Significant differences (p<0.05) were assessed with Tukey’s test. Different letters 
(a,b,c) within each column represent significant differences between the species and species vs. 
etoposide for each cell line. Different letters (A,B,C) within each row represent significant 
differences between the effect of the extracts to the different cell lines; n. s – non-selective (SI=1). 
43 
 
Previous studies addressing the cytotoxicity of ethanol extract of freshwater microalga 
Micractinium sp. reported suppression of proliferation in human colon cancer cells HCT116 
(adherent cell line) at the concentrations of ≥25 μg/mL in a dose-dependent manner86. 
Another freswater microalga Chloromonas sp. showed cytotoxicity against human melanoma 
(A375) and cervical cancer (HeLa) cells with the IC50 value below 25 µg/mL
87
. Ethanol 
extract from marine microalga C. calcitrans displayed high cytotoxicity against human breast 
cancer cell line MCF-7 with IC50 value of 3 µg/mL
88
. These data suggest that results obtained 
with P. tricornutum ethanol extract on HepG2 cells (IC50 = 19.4±2.2 µg/mL) are promising 
and therefore it was decided to test this extract on other cell lines. 
 
3.3. Screening for cytotoxicity of P. tricornutum (PHA) ethanol extract against 
THP-1 cell line 
Since P. tricornutum ethanol extract (PHA ETH)  exhibited the highest cytotoxicity 
towards HepG2 cells, which are considered as more resistant to drugs comparing to other 
cell lines, this extract was further evaluated on a human monocytic cell line (THP-1). 
PHA ETH treatment was again carried out in non-tumoural murine stromal (S17) cells to 
determine the selectivity index. In addition, cells were also treated with etoposide as a 
positive control. As shown in Annex 3  and Figure 10, PHA ETH supressed cell growth 
down to 11.7% at a concentration of 125 µg/mL but already at 62.5µg/mL the survival 
rate increased to 72.4%, indicating that this extract did not display high toxicity towards 
THP1. The calculated IC50 value of 102±7µg/mL was significantly higher than the values 
obtained for this extract on both HepG2 and S17 cell lines (Table 10). Selectivity index 
(SI=0.844) points out that this extract was more selective for non-tumoural cells (S17) 
than leukaemia THP1 cells, which in turn, points to its uneffectiveness. Nevertheless, 
more studies should be performed with other non-tumoural cell lines in suspension, as 
here we only compared THP-1 cells with adherent cell line (S17) and it is expected to 
obtain different responses for adherent and non-adherent cells. The cell line used in the 
study as a healthy control was derived from murine bone marrow and that should be 
considered in the results analysis, as responses to drugs can slightly differ between human 
and murine cell cultures. Additional human-derived healthy controls should be included in 
the study. 
As reported before
80,89
, etoposide was highly toxic to THP1 cells, obtaining significantly 
lower IC50 ( 0.924±0.241 µg/mL) comparing to S17 cells (45.4±0.5 µg/mL) and 
displaying extremely high selectivity (SI=49.4) (Table 10). 
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Table 10. Cytotoxicity (IC50; µg/mL) of P. tricornutum ethanol extract and etoposide against HepG2, 
THP1 and S17 cell lines 
Species  Cell line Selectivity  
  HepG2 S17 THP1 
HepG2vs. 
S17 THP1 vs. S17 
P.tricornutum 
ETH 19.4±2.2
a,A
 85.6±4.4
b,B
 102±7
b,C
 4.40±0.15
a,B
 0.844±0.072
a,A
 
ETOPOSIDE 29.0±3.2
a,A
 45.4±0.5
a,B
 0.924±0.241
a,C
 1.56±0.11
b,B
 49.4±1.2
b,A
 
 
Results are expressed as mean ± SD of data obtained from 3 different experiments performed in triplicates. 
Significant differences (p<0.05) were assessed with Tukey’s test. Different letters (a,b,c) within each 
column represent significant differences between the species and species vs. etoposide for each cell line. 
Different letters (A,B,C) within each row represent significant differences between the effect of the 
extracts to the different cell lines; n. s – non-selective (SI=1). 
 
 
 
 
  
 
Figure 10.  Cell viability (%) after 48 h exposure to different concentrations (0.24– 125 µg/mL) of the 
ethanol (ETH) extract of P. tricornutum and  etoposide on HepG2 and S17 cells . 
 
Although the THP-1 human monocytic leukaemia cell line was firstly derived from a patient 
with acute monocytic leukaemia, this cell line has been used more frequently as a model for 
macrophage differentiation in anti-inflammatory assays than as an in vitro cancer cell 
model
27
. Therefore, there are very few works adressing citotoxicity of natural compounds 
towards this cell line and it is difficult to speculate about the results obtained in this study and 
to compare with other publications. It was demonstrated in two studies that synthetic 
compounds, such as chiral hexacyclic steroids and bis(indolyl)methanes, have anti-cancer 
activity on THP-1 cells with IC50 values in the range of 15.7- 47.3 µM for steroids and 6.34- 
38.8 µM for bis(indolyl)methanes
80,89
. However, when aqueous acetone extracts from twenty-
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one extremophile plant species collected in saline habitats of the South of Portugal (Algarve) 
were screened for anti-cancer properties against THP-1 cell line, none of them showed 
toxicity to these cells, with cell viabilities above 46% after exposure to the extracts (125 
µg/mL) for 72h
90
, which is similar to the results obtained in this study. These results suggest 
that PHA ETH extract might be more toxic to adherent cell lines than to suspension cell lines. 
However, only one adherent cell line and one suspension cell line was tested and in order to 
confirm this, further studies with additional cell lines are needed. Extract tested is a mixture of 
a large number (and variety) of compounds that may interact with each other and purification 
by column chromatography or liquid-liquid extraction needs to be performed in order to 
isolate bioactive compounds with potential anti-cancer activity. Different compounds present 
in natural extracts are mainly defensive chemicals synthesized by the organism after the 
predatory attack or as a stress response to the changes in the environment
91
. There are three 
types of interactions between these compounds found in  natural extaracts: 
additive,synergistic and antagonistic interaction. All three types of interactions are important 
factors that need to be considered when developing a new drug from natural compounds. 
Additive interaction means the effect of two chemicals is equal to the sum of the effect of the 
two chemicals taken separately. This is usually due to the two chemicals acting with the 
similar mechanism
91
. Synergystic interaction means that the effect of two chemicals taken 
together is greater than the sum of their separate effect at the same doses because one 
compound is potentiating the effect of the other one. Synergic interactions are the most 
important characteristics for developing combined therapies in cancer treatment. Substances 
from natural origin and their synergy, allow them to exhibit multitarget mechanism of action, 
as opposed to the conventional “one drug-one target” pharmacological concept.  These 
compounds are able to interact with different targets, modifying different pathways or 
different steps of the same signalling cascade
92,93
. There are also evidences that combined 
therapy consisting of natural extracts and some other chemotherapeutic agent are much 
effective than single-based ones
93
. Antagonistic reaction means that the effect of two 
chemicals is actually less than the sum of the effect of the two drugs taken independently of 
each other. This is because one compound directly blocks the effect of the other. Antagonistic 
reactions form the basis for antidotes of poisonings
91
.  
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3.4. Evalution of cytotoxic activity of fractions obtained from P. tricornutum 
ethanol extract against HepG2, THP-1 and S17 cell lines  
 
In the first phase of this study, the ethanol extract of the marine diatom P. tricornutum was 
identified as the most bioactive in terms of cytotoxicity and selectitvity towards cancer cells. 
In the second phase, the crude ethanol extract was subjected to bioassay-guided sequential 
extraction using hexane, dichloromethane, ethyl acetate and water. The chemical nature and 
the polarity of the solvents used in the extraction process determines the extraction yield, 
composition, and biological activity of a given extract
55
. Hence, solvents of increasing 
polarity were used for the fractionation in order to separate and possibly isolate promising 
compounds responsible for cytotoxicity.   
Four fractions were obtained (hexane, dichloromethane, ethyl acetate and water+ethanol) and 
tested for toxicity against adherent (HepG2) and suspension (THP-1) cancer cell lines via the 
MTT colorimetric assay with 48 h of treatment. Concentrations were applied in the same 
range of concentrations 3.90 µg/mL - 125 µg/mL, as before. The effectiveness of the fractions 
was measured by assessing selectivity and comparing the calculated IC50 values with those of 
etoposide, as showed in previous section. Selectivity was again determined using non-
tumoural murine stromal cells (S17).  
Dichloromethane (DCM) was the most active fraction causing a significant decrease in cell 
viability for both adherent (HepG2) and suspension (THP-1) cell lines. As shown in Figure 11 
and Annex 4, treatment of HepG2 cells with 15.6, 31.2, 62.5 and 125 µg/mL of DCM extract 
for 48h significantly decreased cell viability to 82.1%, 44.3 %,16.6% and 7.19%, respectively. 
For THP-1 cells, at the same concentrations, survival rates were 50.1%, 31.4%, 9.93% and 
5.45%, respectively.  
The calculated IC50 values of 27.5±1.6 µg/mL and 22.3±1.8 µg/mL µg/mL (for HepG2 and 
THP-1, respectively ) were significantly similar (Table 11). Although in both cases the DCM 
fraction displayed IC50 values significantly higher than etoposide, it was more selective than 
this chemotherapeutic agent with selectivity index >4.54 for HepG2 and >5.60 for THP-1 
cells. These results suggest that the DCM extract was equally effective for both adherent and 
suspension cell lines while at the same time, there was no observable toxicity for non-
tumoural cells even when treated with the highest concentration (125 µg/mL). However, as 
explained before, this fraction is still mixture of a great number of compounds which need to 
be characterised and tentatively identified before a promising anti-cancer agent can be 
unveiled. In spite of the large number of publications addressing cytotoxic activity of 
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microalgae against cancer cells, there are no reports so far on the potential in vitro anti-
tumoural activity of dichloromethane fractions of the species included in this study (P. 
tricornutum). Anti-cancer activity against HepG2 and IPC-81 rat promyelocytic leukaemia 
cell lines has been previously described for compounds present in aqueous fraction of P. 
tricornutum methanol extract, inducing more than 30% cell death at concentration of 4mg/mL 
of dry weight
94
. It has been shown as well that sulphated polysaccharides isolated from P. 
tricornutum ethanol extract possess cytotoxic activity against HepG2 cells when applied at 
250 µg/mL
60
. The concentrations reported in these two studies are considerably higher than 
the ones used in our research and confirmed to be toxic to HepG2 and THP-1 cells. As 
mentioned before, previous studies dealing with cytotoxicity of microalgae extracts revealed 
that cytotoxic effect was mainly attributed to the non-polar compounds in the extracts (e.g. 
carotenoids) that are extracted with less polar solvents like hexane, acetone and ether. Water 
is extremely polar, therefore these compounds cannot be extracted in aqueous fraction, hence 
the reason for such high concentrations. In our study, aqueous fraction of P.tricornutum was 
also inactive at 125 µg/mL, as it will be explained in the next paragraph. As for the sulphated 
polysaccharides isolated from P.tricornutum, they were also extracted in hot distilled water. 
When sulphated polysaccharides were isolated from seaweeds, extraction with hot water was 
followed by acetone fractionation. This step might be crucial and would lead to more toxic 
effect on the cancer cells
95
. 
Water and hexane fractions showed no toxicity against both HepG2 and THP-1 cells, as the 
reduction in cell viability did not reach even 50% (Annex 4, Figure 10). As we previously 
decided that IC50 values higher than 125 µg/mL are not promising for anti-cancer drug 
development, they were not subjected to calculation but rather just reported as higher than 125 
µg/mL(>125). Ethyl acetate extract was effective only at a concentration of 125µg/mL for 
both HepG2 and S17, reducing cell viability to 7.85% and 28.9%, respectively. Obtained IC50 
values of 84.2±3.7  and 81.9±2.0 µg/mL for HepG2 and S17, respectively, were again not 
significantly different (p>0.05). In addition to low toxicity, this extract displayed low 
selectivity (SI=1.48), similarly to etoposide (Table 11).  
Prior to fractionation, P. tricornutum ethanol extract was freshly prepared from dry biomass 
and re-tested for cytotoxicity against all three cell lines. Interestingly, the IC50 values for all 
cell lines were significanlty higher (Table 11) than the values obtained with already prepared 
extracts in the first screening (Table 10). As shown in Table 11 and Figure 10, in case of 
THP-1 and S17 cells, this new extract was completely uneffective in a reduction of cell 
viability less than 50% (IC50 > 125.0µg/mL). On the other hand, extract showed cytotoxic 
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effect against HepG2 cells with IC50 of 39.82µg/mL, which was significantly higher 
comparing to P. tricornutum extract initially tested (19.42µg/mL). Besides, the IC50 obtained 
was also significantly higher in comparision to that of etoposide, but still maintaining high 
selectivity (SI > 3.14), suggesting that the extract did not lose its effectiveness (Table 11). 
There are a few factors that need to be taken into consideration and could have contributed to 
the slight loss of the activity between the extracts. The dried biomass was provided by 
NECTON, where microalgae are cultivated on a large scale for different purposes. P. 
tricornutum is used for aquaculture; therefore, culture conditions  are optimized to enhance 
the production of specific bioactive metabolites relevant for aquculture, such as 
eicosapentaenoic acid (EPA) (one type of omega-3 polyunsaturated fatty acid) and the 
vitamins biotin, thiamine and cobalamine. It was previously described that environmental 
conditions during the growth of this diatom (e.g. temperature, light, salinity, nutrient 
availability) have a strong influence on the biomass composition and distribution of different 
metabolites, especially on the lipidic content
96
. This means that the content of potentially 
cytotoxic compounds relevant for this study,  may differ from batch to batch, and differences 
in cytotoxicity results can be expected.   
Taken alltogether, these results, as well as the results presented earlier in this section from 
dichloromethane fraction, still indicate that P. tricornutum ethanol extract has potent anti-
cancer activity and can be considered as a promising candidate in anti-cancer therapy. 
However, additional (further) studies are needed in order to characterise and identify 
compounds which might be responsible for this cytotoxicity. In that sense, dichloromethane 
fraction was selected to be analysed with GS-MS.  
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Table 11. Cytotoxicity (IC50; µg/mL) of fractions (hexane, dichloromethane, ethyl acetate, water+ethanol) 
from P. tricornutum ethanol extract and etoposide against HepG2, THP1 and S17 cell lines  
Extract 
 
Yield (%) 
 
Cell line Selectivity 
  
HepG2 S17 THP1 
HepG2 vs 
S17 
THP1 vs 
S17 
Ethanol crude 
extract 22.40% 39.8±4.3
b
 >125 >125 >3.14
c
 n.s 
Hexane fraction 31.93% >125 >125 >125 n.s n.s 
Dichloromethane 
fraction 16.27% 27.5±1.6
a,A
 >125 22.3±1.8
a,A
 >4.54
b,A
 >5.60
c,B
 
Ethyl acetate 
fraction 5.71% 84.2±3.7
c,A
 >125 81.9±2.0
b,A
 1.48±0.13
a,A
 1.53±0.15
b,A
 
Water+ethanol 
fraction 43.62% >125 >125 >125 n.s n.s 
Etoposide   29.0±3.2
a,A
 45.4±0.5
B
 0.924±0.241
c,C
 15.6±0.1
a,A
 49.4±1.2
a,B
 
Results are expressed as mean ± SD of data obtained from 3 different experiments performed in triplicates. 
Significant differences (p<0.05) were assessed with Tukey’s test. Different letters (a,b,c) within each column 
represent significant differences between the species and species vs. etoposide for each cell line. Different 
letters (A,B,C) within each row represent significant differences between the effect of the extracts to the 
different cell lines; n. s – non-selective (SI=1 
 
3.5. Microscopic examination of morphological changes using inverted 
microscope 
After incubation with tested extracts (125 µg/mL) for 48h, morphological alterations in 
HepG2, S17 and THP-1 cells were observed in comparison to the control (untreated) cells. 
This examination was performed before adding MTT in order to screen for some potential 
apoptotic events in the cells. Phenotypically, apoptosis is characterized by cell shrinkage, 
chromatin condensation, plasma membrane blebbing, DNA fragmentation, loss of contact 
with adjacent cells and collapse of the cell into small fragments (apoptotic bodies)
97
. 
Visualization of the control (untreated) cells showed that the cells maintained their original 
morphology, as in the culture flask (Figure 12); adherent cell lines (HepG2, S17) were 
attached to the bottom of the wells, forming monolayers. THP-1 had round-shape 
appearance,without signs of shrinkage. 
Microscopic evaluation (Figure 12) revealed that both P. tricornutum ethanol extract (PHA 
ETH) and its dichloromethane fraction (DM) decreased the number of HepG2 and THP-1 
cells, and induced cell detachment from the monolayer, in case of HepG2 cells. In addition, 
cell shrinkage could be observed, especially in THP-1 cell lines. These changes resemble 
effects caused by apoptosis, suggesting that both extracts tested might have apoptogenic  
properties; hence, decrease in cell number might be contributed to apoptosis. However, in 
order to confirm this, additional studies are needed, such is Annexin V staining assay and 
DNA fragmentation to identify and quantify apoptotic cells
48
. 
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Figure 11.  Cell viability (%) after 48 h 
exposure to different concentrations (3.9– 
125 µg/mL) of the fractions (hexane, 
dichloromethane, ethyl-acetate, 
water+ethanol) from P. tricornutum ethanol 
(ETH) crude extract and  etoposide, on 
HepG2, THP-1  and S17 cells . 
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3.6. Identification of compounds present in the extract using gas 
chromatography-mass spectrometry (GC/MS) 
 
In the previous section, the dichloromethane fraction was described as the most active with 
promising IC50 values for both HepG2 and THP-1. Besides, this fraction was highly selective 
for HepG2 cells having no observable toxic effect on non-tumouralS17 cells. In order to 
identify compounds with potential anti-cancer properties, this extract was analysed byGC/MS. 
In the GC/MS analysis, a total of 52 peaks were detected, of which 33 were successfully 
identified (Table 12). 
Control PHA ETH  DM  Etoposide 
HepG2 
THP-1 
S17 
Figure 12. Examination of morphological changes on cells with light inverted microscopy.  In order to 
screen for signs of apoptosis, HepG2, THP-1 and S17 cells were treated with  125 µg/mL of P.tricornutum 
ethanol extract (PHA ETH),dichloromethane fraction of the extract (DM) and etoposide. For THP-1 
concentration, etoposide was applied at 7.8  µg/mL. 
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Compound identification was performed by comparative analysis of mass spectral data of the 
detected compounds with those present in the NIST library. Only match scores above the 
treshold (>700) were considered as a positive identification.Thirteen of these compounds 
were previously described inthe literature as promising anti-cancer agents, and could 
contribute for the cytotoxic activity against HepG2 and THP-1 cells observed in this study.   
These 13 compounds can be classified into six different categories : saturated fatty acids 
(SFA) (pentadecanoic acid, hexadecanoic acid, 7-hexadecenoic acid, 9-octadecenoic acid, 10-
octadecenoic acid) polyunsaturated fatty acids (5,8,11,14-eicosatetraenoic acid - ETA, 
4,7,10,13,16,19-docosahexaenoic acid - DHA, 5,8,11,14,17-eicosapentaenoic acid - EPA, 
gamma-linolenic acid, sterols (24-methylcholesta-5,22-dien-3β-ol - Brassicasterol) ,vitamins 
(dl-α-Tocopherol), phenols (2,4-Di-tert-butylphenol) and terpenoid alcohols (phytol). 
Phaeodactylum tricornutum is known for its high lipid content and is considered as an 
important source of the polyunsaturated fatty acids (PUFAs) EPA and DHA; therefore this 
diatom has an important commercial application, especially in aquaculture. Omega-3 or n-3 
fatty acids are the most important PUFAs as they are key nutrients involved in normal growth 
and development of various human tissues. It is also well known that n-3 PUFAs, particularly 
EPA and DHA, are essential for the prevention and reduction of risks of some diseases, such 
as atherosclerosis, cardiovascular disease, inflammation, and mental illness
98
. Several studies 
reported that EPA and DHA can induce apoptosis in tumor cells in vitro and in vivo, in a 
dose- and time-dependent manner. They showed cytotoxicity against a wide range of solid 
tumors (colorectal carcinoma, esophageal, and gastric, ovarian, lung cancers), as well as 
towards myeloid and lymphoid leukaemia and lymphomas
99
. 
Amongst saturated fatty acids (SFAs), hexadecanoic acid waspreviously described as the most 
abundant in this microalga
98
.Looking at the Table 16, it can be seen that the three most 
abundant peaks detected by GC/MS were identified as EPA, hexadecanoic acid and 9-
hexadecenoic acid with 16.67%, 17.44% and 19.56% of total peak area, respectively. 
It was published earlier this year that a lipid fraction containing a mixture of PUFAs (ETA 
and DHA) and SFAs (pentadecanoic acid, hexadecanoic acid, heptadecanoic acid, 
octadecanoic acid, 9-hexadecenoic acid , 7-methyl-6-hexadecanoic acid, 9-octadecenoic acid 
and 11-octadecenoic acid) from a sponge A. sinoxea was active against human colorectal 
adenocarcinoma cell line (HT-29) with IC50 26.52± 8.19 μg/mL
100
. Most of these fatty acids 
were also detected in our sample (Table 12). In another study where plant extracts (Kigelia. 
pinnata) was screened for anti-cancer properties against human colorectal carcinoma cell line 
(HCT 116) and the most active fraction obtained with column chromatography with ether 
53 
 
:acetone (6:4) as solvent system revealed that the active compound was n-hexadecanoic acid 
showing high toxicity with an IC50 of 0.8 µg/mL. Furthermore, it was proposed that the 
observed cytotoxic activity of hexadecanoic acid was due to its high affinity towards 
interaction with DNA-topoisomerase I which makes this fatty acid as a good candidate for 
anti-cancer therapy 
101
. Currently, there are no other evidences of cytotoxicity caused by 
hexadecanoic acid obtained from P. tricornutum.  
Apart from a high content of fatty acids, P. tricornutum is an important source of sterols.  
Sterols play relevant roles in cellular defence and signalling, and they are precursors of 
several hormones and bioactive secondary metabolites. Few reports have dealt with sterol 
biosynthesis in this alga and the major sterol identified was 24-methylcholesta-5,22-dien-3β-
ol (Brassicasterol). Other sterols reported were campesterol, cholesterol and ergosterol
96,102
. In 
this study, we have indetified only one sterol from P. tricornutum - brassicasterol, 
representing 1.86 % of total peak area (Table 12). Anti-cancer properties were also attributed 
to this class of compounds. A sterols-rich fraction from A. sinoxea  was highly toxic to 
adherent cell lines (human colorectal adenocarcinoma (HT 29), breast cancer (MCF-7)) as 
well as to suspension cell line (lymphoblastic leukaemia cell line - MOLT-4) with IC50 values 
of 1.20 ±0.24, 4.12 ± 0.40 and 2.47 ± 0.31 μg/mL, respectively. In adition, the fraction was 
inactive against normal fibroblast cells, exhibiting good selectivity
100
.  
Microalgae are a great source of vitamins and antioxidants. P. tricornutum has high content of 
α-tocopherol (vitamin E) whch is a potent antioxidant heavily involved in the protection and 
prevention of lipid peroxidation in membranes. The antioxidant level in natural phytoplankton 
communities is often species-dependent, varying also with the individual, physiological 
condition, and their strategies to deal with reactive oxygen species. It was earlier reported that 
abiotic stress stimulates production of vitamin E in P. tricornutum KAC 37 strain.
103
 In the 
GC/MS analysis of the active fraction in this study, α-tocopherol was detected representing 
1.16% of total peak area (Table 15). Besides from its cancer-protective properties, Vitamin E 
showed cytotoxicity in previous studies when tested against keratin-forming tumour cell HeLa 
(KB), MCF-7 and cervical cancer (CasKi) cells with IC50 of 18.6, 7.5 and 6.0 µg/mL, 
respectively. These promising results suggests that vitamin E from P. tricornutum could be a 
potential anti-cancer agent. Interestingly, one constituent of α-tocopherol with larger peak 
area than vitamin E itself (Table 12) , was also detected in our extract, and that was phytol. 
Phytol is an acyclic monounsaturated diterpene alcohol also present in chlorophyll and used 
as a precursor for the production of synthetic forms of vitamin E. Phytol is an aromatic 
ingredient used in many fragrance compounds and it may be found in cosmetic and 
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noncosmetic products. It has shown that it possesses antioxidant activity, as well as anti-
inflammatory and anti-allergic effects
104
. Furthermore, an essential oil from C. juttae (rich in 
phytol, 30%) showed strong cytotoxic acitivity against triple-negative breast cancer cells 
(MDA-MB-231) in a dose-dependent manner, reducing cell viability to 2% at 100 μg/mL105. 
Furthermore, this compound  was described as promising  drug for schistosomiasis
106
. Phytol 
could have had a potential cytotoxic effect on HepG2 and THP-1 cells used here and it is of a 
special interest since phytol was not reported previoulsy as an abundant P. tricornutum 
metabolite and no cytotoxicity of this metabolite on HepG2 and THP-1 was described before. 
Despite the great variety of phenols present in P. tricornutum, only one was detected in our 
study - 2,4-bis(1,1-dimethylethyl) phenol also called 2,4-Di-tert-butylphenol (DTBP). This 
phenol belongs to the group of marine metabolites, mostly synthesized by marine bacteria and 
some bacteria living in soils; reportedly, it has antibacterial, antifungal and antioxidant 
properties
107
. In addition, DTBP is a potent anti-tumoural compound, as described previously; 
when tested on keratin-forming tumour cell HeLa (KB), this phenol displayed high 
cytotoxicity with an IC50 of 0.81 μg/mL. For MCF-7 cells, IC50 was 5.75 μg/mL
104
. DTPB has 
not been previously associated with P. tricornutum. 
Our GC/MS results indicate that dichloromethane fraction obtained from P. tricornutum 
ethanol extract contains variety of promising compounds with potential anti-cancer properties. 
At this stage of this research, it is difficult to point out one specific compound responsible for  
observed cytotoxicity. However, the most abundant compounds present in this fraction 
(5,8,11,14,17-eicosapentaenoic acid - EPA) , hexadecanoic and 9-hexadecenoic acid) are 
more likely responsible for the observed effect. Sterols are potent anti-cancer compounds, and 
it is also possible that Brassicasterol caused cell death in cancer cells in spite of the low 
amounts detected in this fraction. Nevertheless, synergic effect of all compunds present 
should not be neglected. In order to investigate this,further studies are needed;the 
dichloromethane fraction should be re-fractionated again, to separate between the fatty acid 
fraction, the sterol fraction and phenols fraction and tested again for cytotoxicty. With this 
procedure,then umber of compounds would be narrowed down in each fraction and it would 
be easier to understand the mechanism behind the cytotoxictiy,and to identify one or more 
compounds with anti-tumoural properties. To our knowledge, this is the first study to report 
the cytotoxicity of P.tricornutum against HepG2 and THP-1 cells. 
However, pharmaceutical industries are constantly  searching for a drug candidates in 
compounds that have not been previously identified and characterized by NIST library. As 
mentioned in the first paragraph of this section, out of 52 detected peaks, 33  were 
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successfully identified using NIST library, with 99.6% of total peak area. Among the 
unidentified compounds, the largest peak represented only 1.05% of total peak area, 
belonging to a compound with retention time of 39.942 min. This means that almost all 
volatile or semi-volatile compounds present in the extract were successfully identified and 
almost all were previously reported as cytotoxic.Taking this into consideration, P.tricornutum 
extract may not be a promising anti-cancer drug candidate. Anyhow, further studies are 
needed to confirm this and either descart this microalga as a potential source of new 
compouds with cytotoxic activities, or find some compounds with desired properties. With 
GC/MS, only volatile compounds in extract were detected.Using some other methods like 
liquid chromatography coupled with mass spectrometry(LC/MS), some new, non-volatile 
compounds responsible for cytotoxic effect could be identified. 
P.tricornutum is not the only microalga that has anti-cancer properties. This area is still being 
investigated by researchers and there is still a great number of unexplored microalgae species 
that could be a source of promising anti-tumoural compounds. Microalgae that come from 
extreme environments (very acidic or alkaline waters, high temperature, light, salinity,polar 
environments and metal concentration)could be of a special interest due to the adaptative 
mechanism that these species developed to cope with these extreme environmental 
conditions
108. Marine organisms have emerged as sources of „alternative“ therapies for cancer 
in the past few years and some anti-tumoural drugs from marine origin have been introduced 
to the market. One example is Ara-C (Cytarabine, Alexan R, Udicil R) isolated from the 
Caribbean sponge Cryptotethya crypta and another one is trabectedin, from the marine 
tunicate Ecteinascidia turbinata
1
. Nevertheless, microalgae have some advantages in marine 
drug discovery than other marine organisms. They produce cytotoxic compounds as 
metabolites and once these compounds are identified and characterized, growth conditions of 
specific microalgae species can be optimized in order to produce more biomass and therefore, 
more compound of the interest.In case of sponges and tunicates, cytotoxic compounds are 
usually produced by bacteria or other microorganisms that live inside these organisms, which 
means that they need to be isolated and grown industrially in order to produce the desired 
compounds
100,109
. Microalgae are photosynthetic organisms that use solar energy and fix CO2, 
without the necessity of additional energy source which would impose higher costs of 
production. Bacteria on the other hand, require large bioreactors that consume a lot of energy 
and in addition, they need a sugar source for their cultivation, which is a large drawback 
comparing to microalgae. In addition, compounds obtained from other marine organisms are 
sometimes so complicated that is almost impossible to synthesize them synthetically, which is 
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another disadvantage of using other marine organisms than microalgae in marine cancer drug 
research
46
 . 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RT Tentatively indetified compound 
% total 
area 
22.589 9-Hexadecenoic acid 19.6 
23.071 n-Hexadecanoic acid 17.4 
30.668 5,8,11,14,17-Eicosapentaenoic acid (EPA) 16.7 
22.199 γ-Linolenoic acid 7,.2 
21.963 3,7,11,15-Tetramethyl-2-hexadecen-1-ol (Phytol) 5.35 
22.065 6,9,12,15-Hexadecatetraenoic acid 2.79 
19.493 Cyclononasiloxane 2.07 
26.974 9,12-Octadecadienoic acid 1.98 
34.453 4,7,10,13,16,19-Docosahexaenoic acid(DHA) 1.88 
29.505 Cyclononasiloxane 1.75 
41.555 Tetrapentacontane, 1,54-dibromo- 1.62 
23.981 Citronellol 1.60 
27.144 9-Octadecenoic acid 1.45 
40.532 Tetrapentacontane, 1,54-dibromo- 1.42 
32.074 Eicosanoic acid 1.38 
28.771 1,3-Dioxolane 1.39 
39.637 Octadecane 1.30 
24.097 24-methylcholesta-5,22-dien-3β-ol (Brassicasterol) 1.21 
41.568 dl-α-Tocopherol 1.16 
39.942 Unknown 1.05 
23.529 Pregna-5,9(11)-dien-20-ol-3-one ethylene 1.03 
26.294 Tetrahydro-2H-pyran 0.98 
38.824 Tetratetracontane 0.92 
39.721 
Ergosta-5,22-dien-3-ol, acetate (Brassicasterol 
acetate) 0.76 
26.696 6,9,12,15-octadecatetraenoate (Stearidonic acid) 0.70 
17.286 2- Propenoic acid (Acrylic acid) 0.69 
27.273 10-Octadecenoic acid 0.58 
20.933 3-Hexadecyne 0.53 
30.532 5,8,11,14-Eicosatetraenoic acid (ETA) 0.52 
26.02 4,7,10,13,16,19-Docosahexaenoic acid(DHA) 0.47 
20.615 Pentadecanoic acid 0.38 
12.585 
2,4-bis(1,1-dimethylethyl) Phenol/ 2,4-Di-tert-
butylphenol 0.35 
15.588 Cyclooctasiloxane 0.31 
30,98 cis-8,11,14,17-Eicosatetraenoic acid(ETA) 0.30 
 
SUM 99.6 
Table 12. Characterisation of compounds presentin dichloromethane fraction by (GC/MS) 
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4. CONCLUSIONS 
 
P. tricornutum is a rich source of lipids, especially of n-3 polyunsaturated fatty acids (PUFAs) 
(eicosapentaenoic acid – EPA, and docosahexaenoic acid - DHA) and fucoxanthin. 
Accordingly, P. tricornutum has emerged in the biotechnology field for various applications, s 
such as a biofuel precursor and recombinant protein expression host due to its biosynthetic 
capacity and high growth rates. This microalga is also a promising future source of the 
carotenoid fucoxanthin which could be used both as an antioxidant and a pigmenter in fish 
aquaculture
98
. However, there are only two reports so far addressing anti-cancer properties of 
this diatom.  
Here, we show for the first time that P. tricornutum ethanol extract has strong cytotoxic 
activity against human hepatocellular carcinoma (HepG2) and human monocytic leukaemia 
(THP-1) cell lines, especially its dichloromethane fraction. Calculated IC50 values for HepG2 
were similar to that of etoposide (p>0.05), a commonly used chemotherapeutic drug in the 
treatment of different types of cancer. Furthermore, the extract showed high selectivity 
towards HepG2 cells, with no observed toxic effect on healthy control cells (S17).  
This is a very important point, since in order for a therapeutic agent to be truly effective, it 
should be toxic to cancer cells without harming normal cells; conversely, conventional 
chemotherapeutics (e.g. etoposide) kill cancer cells, but also strike healthy cells, causing 
adverse effects and severe morbidity. 
GC/MS analysis of the dichloromethane fraction successfully identified 99.6% of compounds 
present in the fraction using NIST library. Among these,13 compounds could potentially 
(according to the literature)be reponsible for cytotoxicity against HepG2 and THP-1 cells. 
Additional studies are needed to isolate specific active compound(s) and to confirm its anti-
cancer properties on the cells used in this study. For this purpose, the fractionshould be further 
fractionated, to obtain sub-fractions potentially more active with a more limited number of 
compunds. Despite the identified compounds with anti-cancer properties, this extract may not 
be the best to look for a promising drug lead due to the fact that almost all compounds in the 
extract are already described and pharmaceutical industries search for drug leads in new 
compounds with original structures. GC/MS analysis detected only volatile compounds, 
meaning that additional analysis is required (e.g., LC/MS) to screen for non-volatile 
compounds with cytotoxic effect on cancer cells.  
There are also certain limitations in this study which need to be taken into consideration. 
More healthy control cells are needed for future studies as here we only report cytotoxicity on 
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S17, which are bone marrow stromal cell, originated from mouse and that are adherent cells. 
Both HepG2 and THP-1 are human-derived cell lines; therefore human-derived healthy 
control cell lines would be also needed to propperly assess selectivity. Concerning the results 
obtained with THP-1, a suspension cell line healthy control should be used because S17 is 
adherent cell line, and cells with different morphology respond to chemotherapeutics 
differently. THP-1 cells were more susceptible to etoposide than HepG2, but more resistant to 
the treatment with the extract.Additional leaukaemia cell lines should be tested, as THP-1 are 
more aproppriate for anti-inflammatory assays. Furthermore, we are not sure about the 
mechanism of cytotoxicity that this microalga exhibited towards selected cell lines. In order to 
investigate whether reduction in cell viability was due to apoptosis, additional assays 
detecting apoptotic cells should be performed in the future.  
Despite the fact that no new structures were identified in the extracts and fractions prepared 
from P.tricornutum, microalgae can be considered a promising source of antitumoural 
compounds and further studies should include screening other species for cytotoxic properties 
against cancer cells. 
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5. ANNEX 
 
 
Annex 1. Cell viability (%) of HepG2 and S17 cell lines after exposure to ethyl acetate (EA) extracts of 
selected microalgal species  
  
 
  
Concentration (µg/mL) 
 
 
Extract 
Cell 
line 3.9 7.8 15.6 31.25 62.5 125 
Control 
DMSO 
PHA 
HepG2 104±7 103±10 92.0±7.7 61.2±3.5 20.1±3.3 6.44±2.73 101±6 95.0±7.4 
S17 104±3 103±5 96.2±3.0 96.1±3.6 80.6±6.9 39.9±10.7 100±6 91.6±6.9 
POC 
HepG2 91.6±6.2 84.6±3.1 75.1±3.8 68.2±2.9 24.2±3.4 14.2±3.8 
 
 
S17 101±6 104±5 101±3 93.5±3.7 93.3±2.0 81.6±2.1 
 
 
ISO 
HepG2 95.6±10.5 87.8 ±8.6 79.6±4.8 65.7±7.1 23.6±4.2 4.92±1.45 
 
 
S17 104±5 104±3 98.9±3.9 93.3±2.6 85.6±4.3 40.6±5.1 
 
 
SKLT 
HepG2 109±6 106±4. 99.4±11.9 68.6±3.4 26.0±2.6 4.88±0.52 
 
 
S17 102±4 99.5±5.8 87.1±8.6 69.2±9.2 45.5±6.0 33.7±5.2 
 
 
NANNO 
HepG2 103±3 94.0±7.0 86.2±10.2 80.7±8.6 74.2±8.0 56.6.±3.8 
 
 
S17 103±5 101±6 93.2±7.1 83.8±14.0 77.1±10.0 57.5±4.2 
 
 
T CTP4 
HepG2 105±11 96.0±5.0 96.6±8.9 95.6±11.2 86.6±7.0 74.2±5.0 
 
 
S17 100±7 101±6 99.1±6.5 91.0±11.3 87.9±11.7 74.0±5.5 
 
 
Etoposid 
HepG2 82.1±6.2 74.2±4.5 62.4±5.6 40.6±5.2 21.2±5.0 9.64±2.81 
 
 
S17 92.9±3.5 91.0±4.0 80.6±4.4 62.4±4.6 62.4±4.6 5.03±0.77 
 
 
DMSO, dimethyl sulfoxide; 
 
 
 Annex 2. Cell viability (%) of  HepG2  and S17 cell lines after exposure to  ethanol (ETH) extracts from 
P. tricornutum (PHA) and Isochrysis sp. (ISO)  
 
    Concentration (µg/mL) 
Control DMSO  
Extract 
Cell 
line 3.9 7.8 15.6 31.25 62.5 125   
PHA 
HepG2 90.2±8.0 81.8±7.9 62.0±4.2 20.8±2.3 13.7±6.6 3.36±0.66 100±1 94.9±7.5 
S17 102±2 99.4±1.9 99.2±1.9 94.9±4.0 89.6±10.1 8.08±3.08 100±4 96.5±5.6 
ISO 
HepG2 95.2±1.7 92.4±2.3 89.1±0.9 87.8±1.2 63.7±4.2 35.8±4.3 
  
S17 102±4 98.5±8.9 95.6±5.1 95.2±8.3 89.4±10.2 15.6±4.8 
  
Etoposide 
HepG2 82.1±6.2 74.2±4.5 62.4±5.6 40.6±5.2 21.2±5.0 9.64±2.81 
  
S17 92.3±3.5 91.0±3.9 80.6±4.4 62.4±4.6 26.1±3.3 5.03±0.77 
  DMSO, dimethyl sulfoxide;  
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Annex 3. Cell viability (%) of THP1 and S17 cell lines after exposure to ethanol (ETH) extract from P. 
tricornutum (PHA) and etoposide  
Concentration 
(µg/mL) PHA  Etoposide Control DMSO PHA Etoposide Control DMSO 
 
THP-1 cell line  S17 cell line 
0.24  - 87.1±11.9 101±5 89.4±3.8 
  100±6 91.6±6.
9 
0.49  - 72.5±5.4 
  
    
0.98  - 51.2±8.2 
  
    
1.95  - 29.8±8.7 
  
    
3.9 101±4 14.9±4.0 
  
103±2 92.86±3.48   
7.8 97.1±4.8 9.15±1.80 
  
99.4±1.9 91.05±3.95   
15.6 88.1±4.5 3.14±1.50 
  
99.2±1.9 80.57±4.40   
31.2 85.31±6.0 - 
  
94.9±4.0 62.38±4.56   
62.5 72.4±10.8 - 
  
89.5±10.1 26.09±3.28   
125 11.7±4.5 - 
  
8.07±3.08 5.03±0.77   
DMSO, dimethyl sulfoxide; 
 
 
Annex 4.Cell viability (%) of HepG2, THP1 and S17 cell lines after exposure to fractions obtained from P. 
tricornutum (PHA) ethanol extract 
DMSO, dimethyl sulfoxide; 
 
    Concentration (µg/mL) Control DMSO  
Extract / 
Fraction Cell line 3.9 7.8 15.6 31.25 62.5 125   
Ethanol 
crude 
extract 
HepG2 95.7±2.3 93.9±1.9 82.0±7.8 63.3±8.8 39.9±9.2 25.1±11.4 100±6 96.6±7.4 
S17 99.3±3.6 1055±2 101±5 97.6±1.9 82.2±4.7 74.2±3.3 102±4 92.9±5.8 
THP-1 103±1 94.5±4.7 87.4±3.7 80.7±2.3 67.5±5.9 56.4±7.6 101±5 89.4±3.8 
Hexane 
fraction 
HepG2 97.9±2.5 93.8±8.4 88.1±10.6 82.1±5.3 63.8±2.3 56.4±2.5 
  S17 108±7 114±7 113±15 110±10 104±9.9 97.4±2.1 
  THP-1 96.1±4.2 95.0±5.4 83.8±11.7 82.3±4.0 83.0±5.6 67.2±3.3 
  
Dichloro- 
methane 
fraction 
HepG2 99.9±7.2 92.8±3.4 82.1±5.7 44.3±5.0 16.6±2.7 7.22±1.84 
  S17 101±3 86.7±5.6 82.5±1.2 74.7±3.2 68.1±9.3 69.0±7.0 
  THP-1 79.8±4.2 65.8±5.0 50.9±2.6 31.4±3.3 9.9±1.0 5.45±0.57 
  
Ethyl 
acetate 
fraction 
HepG2 103±6 98.5±6.7 96.7±11.0 89.7±11.7 63.0±5.6 7.85±1.43 
  S17 105±13 103±8 93.6±10.9 86.0±9.5 86.5±11.4 81.8±6.1 
  THP-1 92.0±1.7 94.8±3.8 91.8±3.9 86.5±4.9 64.2±2.6 28.9±2.6 
  
Water+ 
Ethanol 
fraction 
HepG2 105±3 99.8±4.9 97.9±4.9 92.1±5.4 83.7±7.0 76.9±5.1 
  S17 91.4±7.3 80.7±9.2 86.4±12.5 89.3±5.6 99.2±8.0 90.4±4.4 
  THP-1 89.0±7.6 83.4±5.7 89.6±13.0 85.3±8.9 88.5±5.1 75.7±5.2 
  
Etoposide 
HepG2 82.0±6.2 74.2±4.5 62.4±5.6 40.6±5.2 21.2±5.0 9.64±2.81 
  S17 92.9±3.5 91.0±3.9 80.6±4.4 62.4±4.6 26.1±3.3 5.03±0.77 
  THP-1 14.9±4.0 9.2±1.8 3.1±1.5 - - - 
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